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Abstract
Microvascular dysfunction has been proposed as a linlc between clinical risk 
factors and cardiovascular disease. Many of these risk factors have also been 
proposed to predispose to complications of pregnancy such as pre-eclampsia and 
intrauterine gi'owth restriction. My aims therefore, were to consider cardiovascular 
risk factors in relation to microvascular function in normal and complicated 
pregnancy using the novel, non-invasive teclmique, laser Doppler perfusion 
imaging in an attempt to examine potential mechanisms of such complications.
In chapter two I describe the development of our methodology for in-vivo 
examination of skin microvascular function, using iontophoresis of acetylcholine 
(ACh), an endothelium dependent vasodilator, and sodium nitropmsside (SNP), 
an endothelium independent vasodilator, in conjunction with a laser Doppler 
perfusion imager. A novel feature involved monitoring voltage across the 
iontophoresis chambers during cuiTent application. Both drugs elicited 
vasodilatation but with differing magnitudes and time-courses. During ding 
delivery a 3-4 fold difference in calculated skin resistance was observed between 
subjects, with higher resistairce being associated with lower dilator responses to 
both drugs. This was corrected in individual subjects by multiplyiirg individual 
perfusion values by the resistance.time integral, which reduced response 
variability. Cyclooxygenase iirlribition by aspirin apparently attenuated ACH and 
SNP vasodilator responses but after correcting for sldn resistance this effect was 
no longer observed. We propose that monitoring voltage across the iontophoretic
circuit is critical as the circuit resistance, wliich can be corrected for, influences 
effective dmg delivery in individual subjects.
Iontophoretic assessment of skin microvascular function is complicated by the 
occurrence of electrically induced hyperaemia, especially at the cathode.
Therefore in chapter three I examined the possible mechanisms of this effect in an 
attempt to reduce or eliminate this artefact. I noted voltage across chambers 
containing drug and salt solutions were significantly lower than the voltage profile 
of H2O alone and eliminated this artefact. Voltage.time integral rather than charge 
was the prime deteiminant of electrically induced hyperaemic responses. 
Hyperaemic responses appeared to be prostaglandin dependent as they were 
ablated by cyclooxygenase inliibition. Therefore, use of a low resistance vehicle 
combined with larger chamber sizes and lower currents can prevent such artefacts, 
increasing the robust nature of this methodology for clinical assessment of 
endothelial function.
In chapter four I considered the effects of the increasingly prevalent 
cardiovascular risk factor, obesity, on maternal metabolic and vascular function. I 
examined healthy women in the third trimester of pregnancy and categorised the 
participants into two groups of lean and obese. A detailed panel of metabolic and 
inflammatory parameters was measured and an in-vivo assessment of endothelial 
dependent and independent microvascular function made using laser Doppler 
imaging. As in non-pregnant obese individuals, a significant dyslipidaemia and 
pro-inflammatory phenotype was demonstrated in obese women with leptin and
fasting insulin levels more than double that seen in controls. Both endothelial- 
dependent and independent vasodilatory responses were reduced in obese women. 
CRP (r=0.289, P  =0.049) and insulin (i-0.339, P  =0.02) were related inversely to 
endothelial-dependent function. Such factors may contribute to maternal 
complications in obese women and as a result potentially influence fetal 
prograimning of adult vascular disease.
In chapter five, I examined pregnant women with type 1 diabetes. Our aim was to 
compare vascular function, metabolic and inflammatory risk factors 
prospectively, in the antenatal and postpartiun periods. Microvascular responses 
in both controls and diabetic women were better during pregnancy compared with 
postpartum. Moreover those women with worst ACH response postpartum
showed most significant improvements during pregnancy. Responses in women 
with diabetes were less than controls during both periods despite similar 
lipoprotein profiles. The difference in vascular responsivity between cases and 
controls was attenuated by adjustment for HbAlc, but not CRP concentrations in 
the two gi'oups. I concluded that pregnancy entrances microvascular function, but 
in women with diabetes such improvements are insufficient to attain responses 
seen in healthy non-pregnant women. This suggests a persistent vascular defect in 
women with type I diabetes that may contribute to adverse pregiianey outcome. 
Our data suggest a role for the chronic effects of hyperglycaemia in the impaired 
vascular responsiveness in such women.
In chapter six I examined cutaneous microvascular function in pre-eclamptic 
women. I also considered circulating markers of endothelial damage and 
simultaneously measured lipid and cytokine levels. I considered pre-eclamptic 
women in relation to their first trimester BMI and as pre-eclampsia and intra­
uterine giowth restriction (lUGR) are proposed to arise horn similarly impaired 
placentation, I also examined women with lUGR. To the extent o f our loiowledge, 
most work concerning endothelial function in PET has not considered or 
controlled for the effects of body mass index (BMI). I demonstrated elevated 
concentrations of both fasting leptin and triglyceride in pre-eclamptic women, 
independent o f BMI. Women with lUGR had smaller 1st trimester BMI (p=0.044) 
and 3rd trimester LDL-C concentration (P=0.021) compared with controls. I noted 
a stepwise increase from lean to obese to pre-eclamptic in the concentration of IL- 
6, VCAM-1 and E-selectin. I demonstrated reduced endothelial dependent 
vasodilatation in pre-eclamptic as compared with lean women and responses to 
ACH coiTelated inversely with the inflammatory cytokine IL-6 (r = -0.705, P 
=0.023). However, obese healthy women showed smaller endothelial dependent 
responses than pre-eclamptics. I propose that in-vivo endothelial dysfunction as 
demonstrated by this technique, does not represent the entire pathophysiological 
mechanism in PET. Increased capillary permeability, perhaps secondary to 
elevated placentally derived leptin, may contribute to symptoms of pre-eclampsia. 
Therefore, in-vivo methods of microvascular function assessment are not sensitive 
or specific for the prediction of pre-eclampsia.
Epidemiological studies have recently demonstrated a relationship between pre­
eclampsia and an increased risk of maternal coronary heart disease in later life. 
Common risk factors, either genotypic or phenotypic, may underlie both pre­
eclampsia and coronary heart disease. Therefore in chapter seven I aimed to test 
the hypothesis that insulin resistance, inflammation, and hyperlipidaemia would 
persist in women with a history of pre-eclampsia and secondly that within this 
group there would exist demonstrable endothelial dysfunction. I demonstrated that 
women with a past histoiy of pre-eclampsia have increased plasma concentrations 
of the inflammatory markers, VCAM-1 and ICAM-1 and impaired endothelial 
dependent vasodilatation, 15 years or more after the index pregnancy. In 
conclusion therefore, these data may suggest that the phenotype associated with 
pre-eclampsia is linked to novel mechanisms underlying coronary heart disease.
Therefore, I have developed a robust mechanism for the in-vivo assessment of 
cutaneous microvascular function. Tliis has been used to demonstrate impaired 
microvascular responses in pregnant women with an elevated risk of 
cardiovascular disease in pregnancy and in later life. I have also demonstrated 
impaired microvascular function in women with a past history of pre-eclampsia. 
These observations have been closely related to both traditional (metabolic) and 
novel (inflammatory) cardiovascular risk factors. However, using this technique I 
have demonstrated that in-vivo endothelial dysfunction in women with pre­
eclampsia may be secondary to differences in BMI. Also women with lUGR tend 
to be thinner and have less of an atherogenic metabolic disruption, perhaps
suggesting a systemic cardio-protective role for “leanness” in this group. Leptin 
concentrations are elevated in pre-eclampsia, independent of BMI, and I propose 
roles for leptin both as a placental response to ischaemia and in the 
pathophysiology of pre-eclampsia.
C h a p ter  O ne
INTRODUCTION
Endothelial cell dysfunction: 
implications for women’s health.
A review o f evidence examining microvascular dysfunction 
as a link between shared clinical risk factors and 
cardiovascular disease in pregnancy and later life.
“It will not be foreign to the subject i f  I  here show further, from  certain fam iliar 
reasonings, that the circulation is matter both o f convenience and necessity. In the 
first place, since death is a corruption which takes place through deficiency o f  
heat, and since all living things are warm, all dying things cold, there must be a 
particular seat and fountain, a kind o f  home and hearth, where the cherisher o f  
nature, the original o f the native fire, is stored and preserved; from  which heat 
and life are dispensed to all parts as from  a fountain head; from  which sustenance 
may be derived; and upon which concoction and nutrition, and all vegetative 
energy may depend. Now, that the heart is this place, that the heart is the 
principle o f life, and that all passes in the manner just mentioned, I  trust no one
will deny.-------------  Unless the heart were truly that fountain where life and
heat are restored to the refrigerated fluid, and whence new blood, warm, imbued 
with spirits, being sent out by the arteries, that which has become cooled and 
effete is forced on, and all the particles recover their heat which was failing, and 
their vital stimulus wellnigh exhausted. ”
On The Motion Of The Heart And Blood In Animals, 1628 
W illiam Harvey (1578-1657)
Introduction
Developments in cardiovascular research over the last two decades have 
established the vascular tree to be more than an inanimate conduit for blood, but 
instead a highly complex endocrine and paracrine organ. The vascular 
endothelium is proposed as the mediator of these physiological functions and 
recently an accumulation of evidence has suggested that activation and damage of 
endothelial cells may be the first step in the development of cardiovascular 
disease.
In the healthy vascular tree, smooth muscle maintains a continual state of 
activation secondary to interactions between many chemical and physical factors. 
In 1980 Furchgott and Zawadzld obseiTcd that isolated arteries would 
demonstrate relaxation in response to acetylcholine, but only in the presence of an 
intact endothelium.  ^They postulated that endothelial cells were able to produce a 
diffusible vasodilator, which became known as endothelial derived relaxant factor 
(EDILF). Ignarro and Palmer have since, independently, identified this compound 
as Nitric oxide (NO).  ^  ^This is derived from the tenninal guanidino atom of L- 
arginine, catalysed by the Ca dependent stimulation of enzyme nitric oxide 
synthase (NOS), resulting in production of NO plus L-citruline. (Figure 1) A 
number of other vasodilators, such as bradykinin and substance P, have also been 
shown to require an intact vascular endothelium for their function. Following 
diffusion into the adjacent smooth muscle, nitric oxide (NO) activates soluble
guanylate cyclase, which increases cyclic guanosine 5-monophosphate (cGMP) 
resulting in enhanced sarcolemelle outward transport o f calcium and consequent 
relaxation o f vascular smooth muscle. (Figure 1)
Vascular smooth 
muscle
Endothelial cell
Muscarinic
receptor
Arteriole
cGM P
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Figure I: Mechanism o f  action o f  endothelial dependent and independent vasodilation via nitric 
oxide system, illustrating mode o f  action o f  pharmacological inhibitors o f  NO production. (L* 
NMMA, L-NAME) ACH=acetylcholine, SNP=sodium nitroprusside, NO=nitricoxide, 
eNOS=endothelial nitric oxide sythase, GC=guanylate cyclase, cG M P ^y c lic  guanosine 5- 
monophosphate L-NAM E=NG-nitro L-arginine methyl ester, L-NMM A=NG-monomethyl L- 
arginine
However, NO is not only a potent vasodilator but also inhibits platelet 
aggregation, smooth muscle cell migration and proliferation, adhesion molecule 
expression and consequently monocyte adhesion. Thus NO provides the vessel
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wall with protection against the development of thrombosis and atheromatous 
plaques. Other vascular smooth muscle relaxants produced by the vascular 
endothelium include the eicosanoids, particularly prostacyclin, and the still 
elusive endothelial derived hyperpolarising factor, as well as the vasoconstrictor 
endothelin. Prostacyclin (PGI2) also inliibits platelet aggi'egation by stimulation of 
platelet adenyl cyclase leading to an increase in platelet cyclic AMP. Moncada 
and Vane demonstrated that disease states such as atherosclerosis and diabetes are 
associated with reduced PGI2 production and their observations led to the 
introduction of PGI2 therapy in conditions associated with increased platelet 
aggregation such as haemodialysis and peripheral vascular disease. ^
Many clinical and epidemiological studies have provided evidence that certain 
risk factors, both ti'aditional and novel, can be useful predictors of coronary heart 
disease. Such traditional risk factors include hypercholesterolaemia, particularly 
elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C), 
hypertriglyceridaemia, diabetes mellitus, insulin resistance and obesity.  ^  ^  ^  ^
Novel risk factors encompass the theory of inflammation and include elevation in 
concentration of inflammatory cytokines, soluble adhesion molecules and other 
inflammatory proteins released in response to inflammatory stimulus such as C 
reactive protein (CRP) Each risk factor appears to be inextricably linlced
and may provide an insight into the mechanism by which an alteration in vascular 
function is produced. O f interest, these cardiovascular risk factors are also highly 
significant with regards to the development of some complications of pregnancy,
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particularly pre-eclampsia. Therefore one may hypothesise that in some 
individuals, the metabolic stress of pregnancy may “unmask” those women who 
are predisposed to develop cardiovascular disease in later life. This 
predisposition may be genetically inherited or acquired via in-utero fetal 
programming as has been suggested in Barkers fetal origins hypothesis.
Consequently, in this thesis I will attempt to consider these risk factors with 
regards to vascular function in pregnancy and their influence on such 
cardiovascular complications as pre-eclampsia and intra-uterine growth 
restriction.
Lipoproteins and cardiovascular reactivity
Hypercholesterolaemia is now well established to be a predictor of coronary heart 
disease and more significantly, cholesterol-lowering therapy can reduce the 
incidence of events associated with coronary artery disease. Many studies 
have demonstrated impaired vascular function in association with 
hypercholesterolaemia. Endothelial dependent vasodilatation, in response to 
administration of acetylcholine (ACH), has been demonstrated to be significantly 
impaired in forearm resistance vessels and non-atherosclerotic coronary arteries 
in hypercholesterolaemic patients Other gi'oups have suggested an impainnent 
of endothelial independent vasodilatation as demonstrated by the administration
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of sodium nitroprusside (SNP). Foreaiin blood flow responses to SNP were 
reduced in hypercholesterolaemic patients compared with controls and similar 
results have been demonstrated in isolated resistance vessel preparations from 
hypercholesterolaemic patients O f interest pathophysiologically, this vascular 
dysfimction can be reversed by the restoration of serum cholesterol levels to 
normal or by treatment with anti-oxidant therapy.
It has been proposed that short temi changes in LDL-Cholesterol levels and 
probably more importantly the extent of oxidation of LDL-C modifies both 
vasodilator and vasoconstrictor responses. In animal models of 
hypercholesterolaemia, there is an observed increase in the production of NO 
suggesting a diminished effect rather than reduced production In 1991 Galle et 
al demonstrated that NO liberated from endothelial cells was inactivated by 
oxidised LDL-C and also Schmidt et al observed that NO stimulation of smooth 
muscle guanylate cyclase was impaired in a dose dependent fasliion by oxidised 
LDL. These observations provide mechanistic evidence for the role of oxidised 
LDL in impairment of endothelial dependent and independent vasodilatation. 
Additionally, enlianced NO inactivation may be provoked by oxidised LDL 
stimulated superoxide formation. (Figure 2)
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Figure 2. Mechanisms for oxidant stress-induced endothelial dysfunction in cardiovascular 
diseases (from
Of interest, high-density lipoprotein (HDL) cholesterol has been demonstrated to 
protect against abnomial responses to ACH infusion in coronary arteries and in 
isolated strips of rabbit aorta, HDL reversed LDL induced endothelial dysfunction
30
In the publication of the eight-year follow up data from the PROCAM study, 
serum triglyceride has now been demonstrated to have a significant and 
independent relationship with the incidence of major coronary events.  ^ In a large 
meta-analysis of eight population-based prospective studies, a 1 mmol/1 increase in
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serum tiiglyceride concentration was equivalent to a 14% and 37% increased 
relative risk of coronary heart disease in men and women respectively. The 
mechanism by which triglycerides exert their influence on the development of 
atherogenesis may be variable, including effects on endothelial cell function, 
macrophage loading, tlnombogenesis and determination of LDL size, i.e. defining 
the smaller more dense atherogenic particle size.  ^Of interest, 
hypertriglyceridaemia is strongly associated with non-insulin dependent diabetes 
(NIDDM) consistent with the key role of insulin resistance in both conditions.
Impaired insulin sensitivity and microvascular function
Micro- and macro-vascular complications are problematic in both non-insulin 
dependent (NIDDM) and insulin dependent diabetes (IDDM). In NIDDM, insulin 
resistance and resultant hyperinsulinaemia is proposed as a mechanism by which 
cardiovascular complications such as hypertension arise. Another theory 
suggests increased blood glucose concentrations and the resulting increase in 
glycation products quench NO and therefore impair vascular reactivity.
However in animal models, impaired vascular reactivity was only demonstrated in 
association with prolonged supra-physiological glucose levels hr humans, at 
least one group has demonstrated that a sustained moderate hyperglycaemia of 
10-15 imrol was not associated with impaired vascular function and Morris et al 
observed no relationship between serum HbAlc levels and vascular reactivity in 
NIDDM.
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An alternative hypothesis suggests impaired micro-vascular endothelial function 
in the metabolic ally important capillary beds, as opposed to large vessels, may be 
the precursor to the development of insulin resistance Reduced endothelium 
dependent vasodilatation may result in a decrease in capillary density resulting in 
an increased diffusion distance for insulin and glucose from capillary to muscle 
cells. As a consequence, decreased skeletal muscle capillary recruitment may 
increase total peripheral resistance and therefore blood pressure. Capillary 
endothelial dysfunction may play an important role in the development of the 
atherogenic lipid profile commonly associated with the insulin resistant 
individual, tlirough impaired action of endothelial-bound lipoprotein lipase (LPL) 
resulting in elevated levels of triglyceride and reduced high density lipoprotein 
(HDL). In support of these hypotheses, impaired endothelium dependent 
vasodilatation has been established to be significantly associated with insulin 
resistance and hypertension.
Serne et al demonstrated an inverse relationship between blood pressure and 
insulin sensitivity as well as a strong positive relationship between microvascular 
function and insulin sensitivity. Of interest, waist hip ratio i.e. central body fat 
distribution also shows a strong association with insulin sensitivity, blood 
pressure and microvascular fmiction. Consequently, this gi’oup proposes 
abdominal fat to be a source of free fatty acids (FFA) and cytoldnes, which are 
secreted into the circulation. These circulating factors would promote vascular 
inflammation and endothelial dysfunction, and result in insulin resistance and
16
hypertension as described above. (Figure 3) The deleterious effect of FFA and 
cytokines on endothelial function has been demonstrated previously. ' '
Body composition
- high WHR
- m uscle fiber type II
Defective NO-mediated 
vasodilatation Susceptibility for 
elevated vascular 
resistance
Diminished capillary 
recruitment
HypertensionInsulin resistance
Figure 3. Postulated relations linking insulin resistance and hypertension. Perturbed 
microvascular vasodilator capacity may serve as a common antecedent detennining both insulin 
sensitivity and blood pressure. (From
Insulin dependent diabetes and microvascular function.
Micro- and macro-vascular disease, as seen in complicated insulin dependent 
diabetes (IDDM), has been suggested to arise from a subtly different mechanism 
from that observed in NIDDM. The anatomical distribution of vascular 
complications also varies with peripheral resitance vessel disease predominating 
in NIDDM. Hypertension for example, occurs in as many as 40% of affected
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individuals, whereas small vessel complications of organs such as the kidney, 
brain and retina are more prevalent in IDDM. A vast array of ex- and in-vivo, 
animal and human work has been performed to assess the changes in vascular 
reactivity associated with IDDM. From this work, it appears that endothelial 
dysfunction could arise from a variety of mechanisms such as decreased 
production or enhanced deactivation of NO, impaired diffusion of NO into 
smooth muscle cells or impaired responsiveness of smooth muscle to NO. 
Confusion exists due to the comparison of small and large vessel experiments and 
the assessment of different vascular beds, where endothelial cells may exhibit 
different metabolic and stmctural properties and may be variably influenced by 
hyperglycaemia. In many studies hyperglycaemia is proposed as the mediator of 
vascular complications. Hyperglycaemia is believed to induce multiple changes in 
intracellular metabolism such as activation of the polyol pathway, protein kinase 
C or increasing oxidative stress. Also long term changes in structure and function 
of macromolecules secondary to nonenzymatic glycation and oxidation of 
proteins, results in the foimation of advanced glycation end products (AGEs) and 
may produce alterations in vascular function. (Reviewed in Advanced 
glycation end products (AGEs), form under diverse circumstances such as aging, 
diabetes, and kidney failure. Recent studies suggested that AGEs may form in 
inflamed foci, driven by oxidation. A principal means by which AGEs alter 
cellular properties is tlrrough interaction with their signal-transduction receptor 
RAGE. These receptors have been described in association with increased
concentrations of cellular adhesion molecules and therefore may prime
proinflammatory mechanisms in endothelial cells
In the early stages of IDDM some groups have suggested that increased micro- 
vascular flow and consequent increased capillary pressure can be demonstrated. 
(Reviewed in Up-regulated tissue perfusion results in fiu'ther shear stress 
applied to the vessel wall and consequently the vascular endothelium 
manufactures extra-vascular matrix proteins as an injuiy response. The resulting 
effect is of micro-vascular sclerosis with a consequent impairment in vasodilatory 
reserve and loss of autoregulation. The endpoint of this process would be 
demonstrated in the micro-angiopathic complications commonly associated with 
IDDM. One possible mechanism supporting this hypothesis is demonstrated by 
work performed by Graier et al Tins group demonstrated that cultured 
endothelial cells exposed to supra-physiological concentrations o f D-Glucose 
increase their production of EDRF. Elevated glucose concentrations may also 
result in increased generation of reactive oxygen species. These exert oxidative 
damage to the endothelium with consequent accumulation of glycation end 
products and remodelling of the basement membrane, (Reviewed in
19
Obesity and microvascular function
An elevated incidence of atherosclerotic heart disease is a well-recognised 
association in obese individuals and obesity in isolation is established as an 
independent cardiovascular risk factor. Moreover, the distribution of body fat, 
that is abdominal or central adiposity, has been proposed to be a strong predictor 
of morbidity and mortality and correlates with hyperinsulinaemia, 
hypertriglyceridaemia, reduced HDL concentrations and hypertension.
Steinberg et al employed femoral artery infusion of metacholine and subsequent 
measurement of leg blood flow to demonstrate a 40% reduction in endothelial 
dependent vasodilatation in obese (BMI>28) compared with lean (BMI<28) 
control subjects. More recently Arcaro et al corroborated these findings 
utilising Doppler ultrasound assessment of femoral artery diameter variation in 
response to distal post-ischaemic leg hyperaemia in similarly defined subjects.
A variety of possible mechanisms have been proposed in support of these 
observations including dyslipidaemia, particularly elevated small dense LDL and 
elevated free fatty acids, and relative insulin resistance resulting in 
hyperinsulinaemia. (discussed above)
Inflammation and micro-vascular function.
One potential unifying hypothesis for the effect of lipids, hyperinsulinaemia and 
obesity with regards to endothelial function, involves the theory of 
"inflammation". Arteriosclerosis is now believed to be a disease of inflammation
20
52 and the serum concentrations o f inflammatory markers have been demonstrated
to be predictive of coronary events.
There are several sources of production for inflammatory markers, such as the 
liver, the heart, and circulating cells like macrophages. The inflammatory 
markers, C-reactive protein (CRT) and fibrinogen are derived from the liver under 
the influence of systemic cytokines. CRP and fibrinogen have been demonstrated 
to be independent predictors of cardiovascular events (Figure 4) and Cleland 
et al have recently demonstrated that CRP concentrations, even within the nonnal 
range, strongly conelate with endothelial function as assessed by venous 
plethysmography in a group of healthy subjects
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1. Delermlne TC;HDLC QuinUlo
2. Determine hs-CRP Ouinttic
3. A ssess Cardiovascular Relative Risk
Quintile hs-CRP {mg/L) TCrHDLC (Women) TC.HDtC (Men)
1 0  1 - 0  7 < 3 .4 < 3 .4
2 0 .7  » 1.1 3 .4  - 4 .1 3 .4  .  4  0
3 1.2 - 1.9 4.1 - 4 .7 4 0 - 4 7
4 2 .0  - 3 .8 4 .7  - 5 8 4 7 - 5 6
5 3 . 9 -  15.0 > 5 8 > 5 .5
9•  7
?
A } >5 P!> ad
o/
Figure 4: High-sensitivity C-reactive protein: a novel and promising marker o f coronary heart 
disease
The vessel wall itself produces cell adhesion molecules such as VCAM-1 and 
ICAM-1. These cell surface m olecules are expressed and up regulated in response 
to stimulation by cytokines and their soluble component can be measured in the 
blood. Their purpose is the recruitment o f  circulating inflammatory cells and the 
eventual transmigration o f  the cells through the endothelium, a step believed to be 
the initiating step in the development o f  atheromatous deposits. Ridker et al have
22
demonstrated soluble ICAM-1 concentrations also to be an independent predictor
of cardiovascular events
Specific cytokines such as inteiieuldn-ip, (IL-lp) interleukin-6 (IL-6) and tumour 
necrosis factor a  (TNFa) are largely responsible for the increased expression of 
inflammatory markers by the liver and the endothelium and in a recent study, IL-6 
was predictive of the risk of myocardial infarction despite adjustment for CRP 
concentrations. In cardiovascular disease, a potential soui'ce for the production 
of such inflammatory cytokines may be the myocardium or the atherosclerotic 
plaque itself. However, adipose tissue is increasingly recognised as a source of 
cytoldnes such as IL-lp, IL-6 and TNFa. IL-6 has been proposed as a key 
element in the pathogenesis of cardiovascular disease through a variety of 
mechanisms involving the stimulation of peripheral inflammation as discussed 
above. Also IL-6 concentrations are strongly associated with central 
adiposity, hypertension and insulin resistance, that is the features of the 
dysmetabolic state. (Figure 5)
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F igure 5. The role and regulation o f IL-6. (from **)
MATERNAL CARDIOVASCULAR AND METABOLIC ADAPTATIONS 
ASSOCIATED WITH UNCOMPLICATED PREGNANCY
On achievement o f  conception, the developing embryo implants into the maternal 
decidua and commences an outstanding cascade o f events designed to beneficially 
alter the maternal environment in order that the developing fetus may be 
optimally maintained and nurtured These physiological changes are imperative 
for the achievement o f a successful and uncomplicated pregnancy and failure can
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result in detrimental and life tlireatening effects not only for the fetus, but also for 
the mother.
The Maternal Vasculature in uncomplicated pregnancy
O f particular interest are the maternal systemic cardiovascular adaptations. 
Maternal systemic vascular resistance falls early in pregnancy and therefore, 
despite a 40% increase in cardiac output (20% within the first eight weeks of 
pregnancy) and a 50% rise in circulating blood volume, maternal blood pressure 
begins to decrease towards the end of the first trimester. The nadir of systolic and 
diastolic pressure is attained by aromid 22-24 weeks gestation and thereafter a 
steady rise in blood pressure is observed, until pre-pregnancy levels are achieved 
by term.
Gant et al first demonstrated the resistance of the maternal cardiovasculature to 
the effects of the vasoconstrictor agent, angiotensin II (Agll) and it is now 
generally accepted that pregnancy results in a reduced pressor response to many 
physiological vasoconstrictors such as adienaline, noradi’enaline and the 
eicosanoids. This reduced sensitivity to pressor agents must contribute to the 
overall vasodilatation of nomial pregnancy. In support of this, Everett et al 
demonstrated that in normotensive women, responsivity to Agll can be restored 
by prostaglandin synthetase inliibitors such as Apirin and Indomethacin. 
Broughton Pipkin et al also observed that simultaneous infusion of Agll with
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prostaglandin E2, blunted the pressor effect associated with Agll, suggesting a 
role for prostaglandins in the mechanism of this effect. Everett also described a 
restoration of the refractory nature of the maternal cardiovascular system to the 
pressor effects of Agll, with intravenous infusion of the progesterone metabolite, 
5alpha-pregnan-3,20-dione.
As a consequence of the ethical considerations involved in research concerning 
human pregnancy, most of the work performed in this field has been either animal 
based or ex-vivo human experiments. These techniques represent either an 
indirect assessment of vascular function such as demonstration of circulating 
serum markers of vascular activation or direct, such as isolated vessel wire 
myography.
Most groups now accept that peripheral vasodilatation associated with healthy 
pregnancy is a result of up-regulation of an endothelial-derived vasodilator such 
as prostacyclin (PGI2), EDHF or nitric oxide (NO). (See above) A significant 
increase in the synthesis of PGI2 during pregnancy has been demonstrated and 
patients who develop pregnancy-induced hypertension exhibit a lesser increment 
in prostacyclin biosynthesis than healthy pregnant subjects Animal 
experiments have suggested an increase in NO synthesis in healthy pregnancy. 
Weiner et al demonstrated an up-regulation of calcium dependent NO synthase 
(NOS) activity in a variety of tissues in pregnant guinea pigs, while other
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groups have observed increased nitrate excretion in the pregnant rat. In the 
human, increased excretion of cGMP, the second messenger responsible for 
mediating NO-induced vasodilatation, has been reported in healthy pregnant 
women as has increased nitrate turnover in women with a carefully controlled 
nitrate intake. Both of these observations indirectly suggest the stimulation of 
NO synthesis in association with pregnancy.
The literature concerning human studies of endothelial flmction in pregnancy is 
somewhat contradictory. McCarthy et al were unable to demonstrate a difference 
in ACH responsiveness and therefore endothelial function between subcutaneous 
arterioles obtained at Caesarean section and from vessels obtained from non­
pregnant women during routine surgery. This obseiwation has since been 
reproduced by Pascoal et al using omental vessels from pregnant and non­
pregnant pre-menopausal women exposed to ACH and bradykinin. In an 
experiment using isolated arterioles from subcutaneous fat, no difference was 
seen in the vasoconstrictor response to norepinepluine between those samples 
from pregnant and non-pregnant individuals, before and after denuding the 
vessels of endothelium. However, vessels from normotensive pregnant women 
demonstrated a significantly greater relaxation when exposed to bradykinin than 
those vessels from non-pregnant women. These effects were felt to be dependent 
of endothelium as denuding the vessels obliterated the relaxation. Also 
indomethacin, a cyclo-oxygenase inhibitor, had no effect on vessel relaxation and 
therefore the effect was felt to be NO, but not prostacyclin dependent. Cockell
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et al demonstrated a significant difference (p<0.01) in a study of isolated 
subcutaneous vessels from healthy pregnant and non-pregnant women exposed to 
increase of flow and therefore shear stress. Vessels from pregnant women 
demonstrated a greater relaxation to shear stress and this was attenuated by the 
NOS inliibitor N-nitro-L-arginine methyl ester (L-NAME) suggesting a possible 
mechanism for the fall in peripheral vascular resistance in healthy pregnancy.
In a study of cultured, isolated hand vein endothelial cells, intracellular calcium 
response to adenosine triphosphate (ATP) administration was measured in 
pregnant and non-pregnant women. The endothelial cell response to ATP was 
significantly greater in the pregnant as compared with the non-pregnant group. 
These data suggested a difference in the responsiveness of venous endothelial 
cells in pregnancy. Williams et al performed one of the few functional, in-vivo 
studies to identify differences in vascular reactivity in pregnant and non-pregnant 
women. Using venous occlusion plethysmography, hand blood flow was 
assessed in tlrree gioups of women: non-pregnant, first trimester pregnancy and 
third trimester pregnancy. Basal blood flow was significantly increased in late 
pregnancy as compared with early and non-pregnant subjects (p=0.007) and 
brachial artery infusion of the NOS inhibitor L-NMMA (Figure 1) produced a 
greater reduction in hand blood flow in both pregnant groups compared with the 
non-pregnant women. (p=0.0003) Also vasoconstriction, that is reduced hand 
blood flow in response to administration of norepinepluine, was less in non­
pregnant and early pregnant women as compared with those in late pregnancy. 
(p==0,0029) These observations were confirmed by similar work perfomied by
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Anumba et al. Again, the above evidence suggests that increased generation of 
endothelial cell derived nitric oxide may be the responsible mechanism for the fall 
in peripheral vascular resistance seen in normal human pregnancy.
Maternal Metaholism
Plasma cholesterol and triglyceride concenh'ations increase by 25-50% and 200- 
400% respectively tln'oughout healthy pregnancy. In the latter stages of the 
second trimester of pregnancy an increased concentration of free fatty acids 
(FFA) is obseiwed. This response may be produced as a result o f stimulation of 
hormone sensitive lipases (HSL) by human placental lactogen (FIPL) and/or the 
development of a relative resistance to insulin with a loss of the usual suppressive 
effect of insulin upon FFA release from adipose tissue, (reviewed in (Figure 
6) Therefore an increased delivery of FFAs to the liver results in increased 
synthesis of triglyceride and subsequent hepatic assembly of VLDL particles. 
(Figure 6) Also pregnancy results in a significant reduction in lipoprotein lipase 
activity, with consequent reduction in maternal triglyceride catabolism.
Driven by elevated oestrogen concentrations which stimulate increased Apo A1 
production, high-density lipoprotein (HDL) also increases in pregnancy, 
achieving a peak around 28 weeks gestation. Low-density lipoprotein (LDL) 
achieves a less significant elevation, although as triglyceride concentrations rise, a
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tlneshold is reached after which proportionally more hepatic production o f the 
subfraction LDL-III takes place. In the oxidised form, this molecule is believed to 
be highly atherogenic, promoting foam cell production and initiating endothelial 
dysfmiction. (Figure 6)
Therefore, as discussed above, excess peripheral lipolysis of fat stores provides 
increased non-esterified fatty acid (NEFA) concentrations. NEFAs, as already 
discussed, contribute to the dyslipidaemia observed in pregnancy but in addition 
impair peripheral glucose uptake and enhance glucose production as well as 
possibly inhibiting portal insulin extraction, resulting in increased insulin 
resistance and insulin concentrations. A progi'essive increase in nutrient 
stimulated insulin responses consistent with insulin resistance has been described 
in nomial healthy pregnancy. Hyperinsulinaemic euglycaemic clamp 
techniques have demonstrated insulin efficacy to be as much as 50-70% less in 
late pregnancy as compared with non-pregnant women. To meet the increasing 
demands of the developing fetus and placenta, basal endogenous hepatic glucose 
production is thought to increase by 16-30% with an increased contribution of 
carbohydrate to oxidative metabolism in late pregnancy, (reviewed in
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Cardiovascular and metabolic complications of Pregnancy
1) Pre-eclampsia
Pre-eclampsia is a pregnancy-specific multi-system maternal syndrome, unique to 
humans, encompassing three main clinical aspects: elevated blood pressure, 
proteinuria and oedema. Historically, as the nomenclature suggests, it was the 
complications of this condition that were originally recognised and described, 
with the term “eclampsia” describing maternal seizures. However, pre-eclampsia 
is notoriously heterogeneous with a variety of clinical presentations and 
associated signs and symptoius. The condition is defined as developing after 20 
weeks gestation, most commonly in the third triiuester of pregnancy. The 
comiuon factor in all cases appears to be the presence of the placenta hr cases 
of excessive trophoblastic developiuent such as a molar pregiancy, presentation 
has been described in the first trimester.
The complications of pre-eclampsia can detrimentally affect maternal and fetal 
well being. Cerebral haemorrhage and adult respiratory distress syndrome 
(ARDS) have persistently featured as among the most common causes of 
maternal mortality in the confidential enquiry into maternal deaths in the UK. 
Perinatal mortality associated with this condition is around five times greater than 
that associated with normal pregnancy and the offspring of pre-eclamptic 
pregnancies account for 40% of iatrogenic premature deliveries. Despite these
31
dramatic statistics, delivery remains the only effective strategy for management of 
this condition
As already described, pre-eclampsia is a multisystem disorder with potential to 
develop complications affecting almost all the major systems. These include 
cerebral vasospasm and haemorrhage, resulting in seizures, hepatic and adrenal 
haemorrhage and necrosis, glomerular endotheliosis and acute renal failiue, 
subendocardial necrosis, consumptive coagulopathy and microangiopathic 
haemolysis. Some associated syndromes have been described as potential 
variations of pre-eclampsia. The liver and coagulation pathways are often 
involved with clinical presentation ranging from a mild derangement of liver 
enzymes to gi’oss hepatic impairment and intravascular haemolysis as seen in the 
HELLP syndrome (haemolysis, elevated liver enzymes and low platelets). 
(Reviewed in
Pre-eclampsia is also thought to be associated with an increased risk of 
cardiovascular disease in later life. Of interest, other poor outcomes of pregnancy, 
such as pre-term labour, a small baby and gestational diabetes have also been 
described to be associated with an increased risk of cardiovascular disease in the 
mothers in later life. (Reviewed in ^^ ) (Table 1) Hannaford et al studied general 
practitioners' records of 23000 women from UK in order to determine the rate of 
cardiovascular disease in parous women. Compared with parous women with no
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history of pre-eclampsia, those previously affected by pre-eclampsia showed an 
increased risk of hypertensive disease (RR 2.35), acute myocardial infarction (RR. 
2.24), chronic ischaemic heart disease (RR 1.74), and angina (RR 1.53). More 
recently these findings were confirmed in a local population. Smith et al 
examined data from 130,000 deliveries in Scotland between 1981 and 1985 
inclusive. This was linlced with data on all hospital admissions and the General 
Registrars office, providing follow up infomiation for 15-19 years. Again a two­
fold increased risk o f IHD in women with a past history of pre-eclampsia was 
demonstrated, but of interest, a cumulative risk associated with other 
complications of pregnancy was obsei'ved. Pregiancies affected by pre-eclampsia 
plus pre-temi delivery were associated with a six-fold increase in risk of death 
from IHD compared to women with uncomplicated pregnancy. Pre-eclampsia and 
a baby in the lowest quintile for birthweight was associated with a four-fold 
increase in risk and a combination of all tluee poor outcomes a sixteen-fold 
increase in risk, some eight times the risk from pre-eclampsia alone. This group 
hyothesised that their findings may be explained by common genetic risk factors 
implicated in both the pathophysiology of poor pregnancy outcome and 
cardiovascular disease. An increased risk of insulin resistance has also been 
observed in a seventeen-year follow up of women affected by pre-eclampsia.
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AssLvi;iiioii o fa iv er b o  pregnancy cH tcoiiw s wilh risk o f  d ia tv le s  or risk faclors for a x o n a ry  h a m  d isease  and u i s a ib r  disease
Incidence In Risk factoi’s show n to 
Pregnancy outcom e pregnancy perturbed after A ssociation or i1sk radio (95%  CT)
(%)
(io sta tlon a l dlalx?tcs 1.9-5.0* IJpkls-
Blood p ressu re’
Large vessel fiinerioii' 
Sm all vessel function '
Increased  risk  o f  tv])e 2 dlalvetes, 
especially If recurrence o f  
gestational d iabetes In a 
subsequent pregnancv . No data  
on coronary heart d isease  risk
PrcH‘clam |K la 2-4 Llpkls^
(lotting^
Fasting Insulin^
Large vessel function*
1.9 (1 .0  to 3 .5) pregnancy  
Induced hypertension a lon e’
1.7 (1J  to 2 .2) V no pre-eclam psia*  
2.0 (1 .5  to 2 .5) V no pie-eclam psla*
U w  biKh weight (<25(H) g) 5 N ot studied IL.M .L5 to .16.1)1”  .3500 g" 
7.1 (2.6 to 18.7)1”  .3500 o'*
Preterm  deliver) (<37 w eeks) 5 6 N ot studied 1.8 (1.3 to 2.5) 1’ term deliver)*  
2.1 (1.2 to .3.5) 1' term  d e liv er )"
TX'pendenl on jvpulatksi slikiiovl elhnic ^roup. and diagiK»sric criteria.
Table 1. Complications of pregnancy and associated relative risk of maternal cardiovascular 
disease in later life (From
Pathophysiology
The pathophysiology o f  pre-eclampsia remains unclear, although there is 
increasing evidence that abnormal endothelial function may be implicated. O f 
significance, risk factors associated with the development o f  cardiovascular 
disease in later life, such as dyslipidaemia, insulin resistance and obesity, are also 
strongly associated with pre-eclampsia. The obese individual often demonstrates 
many o f  these risk factors with a resultant increase in the risk o f  developing 
hypertensive complications o f  pregnancy. Sattar et al demonstrated a nine-fold  
increase in the risk for development o f  pre-eclampsia in primigravid wom en with
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a body mass index (BMI) over 25kg/m2 (OR 9.3, 95%CI 2-48). In another 
study of 5800 UK females, the elevated risk of pre-eclampsia associated with a 
BMI greater than 28.6kg/m2 was tliree-fold. (OR 3.02, p<0.0001)
Insulin dependent diabetes and gestational diabetes are also believed to be 
strongly associated with development of hypertensive complications of 
pregnancy. In a large study of 4589 healthy nulliparous women in America, even 
within the normal range, the level of plasma glucose after a 50g oral glucose 
challenge was positively coiTelated with likelihood of pre-eclampsia. Among 
women with gestational diabetes the relative risk of all hypertensive disorders of 
pregnancy were significantly increased (relative risk 1.54, 95% Cl 1.28-2.11)
In another smaller study from Europe, pre-eclamptic women were found to have 
37% lower insulin sensitivity than normal pregnant controls (p=0.009) with 70% 
higher free fatty acid concentrations (p=0.004). Also of interest, insulin sensitivity 
in pre-eclamptic women was still 26% lower than controls some three months 
post-partum (p=0.04) and persistent insulin resistance was demonstrated in a 
seventeen-year follow up of women with pregnancy complicated by pre­
eclampsia.
Pre-eclampsia has been postulated to be an "inflanunatory disorder" with 
endothelial cells in maternal systemic vessels becoming activated and damaged by 
circulating factors released from a poorly perfused and ischaemic placenta 
Therefore, it would seem likely that the classical clinical picture of the
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hypertensive, proteinuric patient is an illustration of the endpoint rather than the 
cause of this complicated condition, hi fact, many of the pathophysiological 
changes associated with pre-eclampsia are demonstrable long before the full 
clinical syndrome becomes evident.
Increased sensitivity of the maternal vasculature to pressor agents such as 
angiotensin II can be demonstrated before hypertension develops although in 
recent studies this has not been confimied Markers of activation of the 
coagulation cascade, such as reduced antitlirombin increased tluombin- 
antitlii'ombin complexes (TATs) and increased fibrin degradation products 
(FDPs) can be demonstrated weeks to months before the development of the 
clinical disorder. Vasoconstriction can also be demonstrated before any clinical 
changes in systemic vascular resistance. Women destined to develop pre­
eclampsia have reduced plasma volume but despite this finding, demonstrate 
increased plasma concentrations of atrial naturetic peptide (ANP) and reduced 
rennin concentrations weeks before pre-eclampsia is clinically evident.
Fasting triglyceride concentrations are doubled compared with normal pregnancy 
and a three-fold increase in VLDL and LDL-III concentrations are also obseiwed 
well in advance of the clinical manifestations of the disease. As described 
above, these changes predispose to endothelial damage and insulin resistance. It is 
also notable that the specific vascular lesion of pre-eclampsia ‘acute atherosis
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with lipid laden foam ceils’ as observed in the placental bed, is similar to that seen 
in arteriosclerosis in the non-pregnant (Figure 6).
Release o f agent(s) 
stim ulating excessive 
lipolysis ?
Insulin resistance
Adipocyte pool
placental iNEFAs
Foam cells in 
spiral arteries
Decreased
peripheral
catabolism?
Oxidised
LDL Inflammatory
mediators
Substantially increased 
circulating (atherogenic) 
lipid pool
Endothelial activation
L i v e r
Hypertension >
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Figure 6: The potential role o f  a disturbance in lipid metabolism in the pathogenesis o f pre­
eclampsia. Placenta factor(s) enhances peripheral lipolysis which is already stimulated in normal 
pregnancy by HPL. This results in an increased flux o f  non-esterified fatty acids (NEFAs) to the 
liver. These are channelled predominantly into hepatic triglyceride synthesis with increased 
secretion (over and above normal pregnancy) o f  triglyceride-rich lipoproteins (VLD L,) 
Accumulation o f  triglyceride occurs in the hepatocyte when this pathway is saturated. Increased 
concentrations o f  VLDL, in the circulation drives the production o f  an atherogenic lipoprotein 
profile by stimulating excessive synthesis o f  small, dense LDL (LDL-III) and by lowering HDL- 
cholesterol. This lipid profile may contribute to endothelial dysfunction and therefore the 
expression o f  pre-eclampsia in the mother. Finally, this pathway plays a part in the formation o f 
lipid-laden macrophages (foam cells) in the spiral arteries o f  the decidua basal is, and as a result, 
may be involved in the enhanced placental production o f  pro-inflammatory mediators in PE. ^
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As discussed above, pre-eclampsia is believed to be a disease of the maternal 
inflammatory system and there is now substantial published evidence in this field. 
Granulocytes and monocytes are activated with increased release of
pro-inflammatory cytokines such as TNFa, IL-6 and soluble phospholipase A2.
An increase in serum concentiutions of the cell adhesion molecules, VCAM-1 
and ICAM-1, has been demonstrated in women with pre-eclampsia also
suggesting a state of inflammation and endothelial activation. Further evidence of 
the link between inflamiuation and endothelial activation is provided by Greer et 
al. This gi'oup have shown that a significant coirelation exists in patients with 
pre-eclampsia, between serum levels of IL-6 and VCAM-1 (r=0.539, p<0.005) 
suggesting, as is seen in cardiovascular disease, that the pro-inflamiuatory 
cytokine IL-6 may be pivotal in the pathophysiology o f endothelial dysfunction 
and the development of pre-eclampsia.
As discussed earlier, more direct evidence of impaired endothelial function is 
difficult to obtain due to ethical issues of invasive testing in pregnancy. However, 
several ex-vivo teclmiques have supplied evidence of altered vascular reactivity in 
pre-eclampsia. Many gi’oups, using various myographic teclmiques, have 
demonstrated reduced endothelial dependent vasodilatation in isolated 
subcutaneous resistance vessels from women with pre-eclampsia  ^ This 
effect was demonsfrated in response to endothelial dependent vasodilators, 
acetylcholine and bradykinin or to sheai' force, also believed to be a stimulant of 
endothelial cell function. Hayinan et al related lipid concentrations, specifically
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lower apo-AI levels (the major lipoprotein in HDL particles), to impaired 
endothelial function in myométrial vessels bathed in plasma from pre-eclamptic 
pregnancies again providing potential evidence of the detrimental effect of a 
circulating factor upon endothelial function. This effect was also demonstrated 
when isolated myométrial vessels from healthy pregnant women showed reduced 
endothelial dependent vasodilatation when incubated with plasma from pre­
eclamptic women.
Venous occlusion plethysmogi'aphy provides a direct technique for vascular 
function assessment but is an invasive technique that is usually combined with 
intra-arterial infusion of potent vasoconstrictors. Anumba et al infused 
incremental doses of the nitric oxide synthase inhibitor, n-monomethyl-L-arginine 
(L-NMMA) and recorded vasoconstrictor responses in non-pregnant, pregnant 
and pre-eclamptic women. (Figure 1) Also, the same investigators employed an 
infusion of the endothelial dependent vasodilator, serotonin, to study these gioups 
of women. These authors failed to demonstrate that reduced nitric oxide activity 
contributes to the increased vascular resistance in pre-eclampsia.
2) Intra-Uterine Growth Restriction (lUGR)
Growth restriction in the neonate is unfortunately, more commonly identified 
after delivery than antenatally. This faihne of antenatal detection is secondary to
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inadequate effective screening tests. "Routine" ultrasound in the third trimester is 
usually arranged as a result of clinical concern or as a result of identifying a "high 
risk" pregnancy, that is an individual with a previous poor obstetric outcome or a 
complicated medical history.
Small for gestational age infants are defined as those with birth weights less than 
the 10* centile or two standard deviations below the mean for gestational age. 
However, the majority of this group are in fact normal healthy infants and do not 
have any particular increased perinatal morbidity or mortality. Also, growth charts 
for different ethnic gioups must be considered, as the children of Asian parents 
cannot be assessed by western parameters. The classical, at-risk, growth restricted 
fetus or infant has a birth-weight under the fifth or even the third centile for 
gestational age, plus or minus abnormal umbilical artery Doppler flow velocity 
waveforms, including absent or reversed end-diastolic flow These babies have 
a perinatal morbidity rate in the range of about 40% and may require 
premature delivery in order to pre-empt intra-uterine death
The causes of growth restriction are varied and in general can be divided into two 
separate groups: intrinsic or syiumetrical growth restriction and extrinsic or 
asymmetrical growth restriction. The symmetry in question is that between the 
growth of the fetal head and abdomen. Asymmetrical growth patterns involve 
"head sparing"; preferential slumting of blood to cerebral vasculature, and
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impaired hepatic glycogen storage and this effect is usually secondary to 
“extrinsic” causes. Intrinsic causes of poor growth are usually fetal in origin, for 
example cliromosomal abnomialities and congenital infections such as 
toxoplasmosis, rubella and cytomegalovims. The outcome for these children is 
extremely poor in general. Extrinsic causes of poor fetal gi'owth usually result 
from impaired placentation, either as a primary phenomenon or secondary to 
maternal medical conditions such as hypertension or social factors such as 
smoking
The normal development of the placental vasculatui’e relies on two distinct waves 
of trophoblastic invasion into the uterine spiral arterioles in the first and second 
trimesters of pregnancy. Failur e of the secondary wave of trophoblast invasion 
into the myométrial segments of the spiral arterioles is observed in the placentae 
of growth restricted fetuses and in pregnancies complicated by pre-eclampsia 
(Figure?).
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Figure 7. (A) Diagram of a longitudinal section o f an anchoring chorionic villus (AV) at the fetal- 
maternal interface at (approximately) 10 wk gestational age. The anchoring villus (AV) functions 
as a bridge between fetal and maternal compartments, whereas floating villi (FV) are suspended in 
intervillus space and are bathed by maternal blood. CTB in AV (Zone I) form cell columns (Zones 
II & 111). CTB then invade uterine interstitium (decidua and first third of the myometrium, (Zone 
IV) and maternal vasculature (Zone V), thereby anchoring the fetus to the mother and accessing 
maternal circulation. (B) Diagram of spiral artery in which endovascular invasion is in progress 
(10-18 wk gestation). Endometrial and then myométrial segments of spiral arteries are modified 
progressively. In fully modified regions (a) the vessel diameter is large. CTB are present in lumen 
and occupy entire surface o f vessel wall. A discrete muscular layer (tunica media) is not evident, 
(b) Partially modified vessel segments. CTB and maternal endothelium occupy discrete regions of 
vessel wall. In areas o f intersection, CTB appear to lie deep to endothelium and in contact with 
vessel wall, (c) Unmodified vessel segments in myometrium. Vessel segments in superficial third 
of myometrium will become modified when endovascular invasion reaches its fullest extent (by 22 
wk), while deeper segments o f same artery will retain their nonnal stnicture. (From ' ‘^ )
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This abnomial implantation can be detected by Doppler ultrasound assessment of 
the uterine artery blood flow, when a high resistance circulation and a “notched” 
appearance to the waveform would be detected. Tins abnormal utero-placental 
circulation is believed to result in hypoxia and ischaemic damage of the placenta. 
However, what is poorly understood is why, with a similar placental abnormality, 
should some women be spared the systemic effects of widespread vascular 
damage and dysfunction manifest as hypertension and proteinuria. Little is laiown 
about maternal metabolism in association with pregnancy affected by intrauterine 
growth restriction. Maternal risk factors are similar to tiro se associated with 
hypertensive disease in pregnancy, such as pre-existing hypertension, renal 
disease, and diabetes, that is maternal vascular disease. In fact, pre-eclampsia and 
lUGR often co-exist although lUGR can also occui' in isolation.
Maternal metabolism associated with lUGR,
In 1985, Knopp et al demonstrated maternal ApoA-I (the principle apoprotein 
associated with HDL2 subfraction) to correlate positively with birth weight while 
ApoA-II (associated with the smaller HDL3 subfraction) correlated negatively 
with birth weight. More recently, Sattar et al demonstrated that in women with 
lUGR there is a failure of the physiological hyperlipidaemia of pregnancy, in 
stark contrast to pre-eclampsia where, as discussed above, an exaggerated rise in 
lipids is observed. In this study, no significant differences were found between 
triglyceride, HDL-C and VLDLi-C between pregnant women with lUGR and
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healthy controls. However women with pregnancies complicated by lUGR had 
significantly lower cholesterol LDL-C, VLDL-C and IDL-C concentrations 
(p<0.01). HDL-2 sub fractions stimulate and may affect fetal gi’owth by 
controlling the provision of cholesterol via the placenta. Another unifying 
hypothesis involves insulin resistance as this relates inversely to HDL 
metabolism. Support for this theory is demonstrated in a study by Breschi et al 
when in women with a BMI less than 25 kg/m^, plasma insulin and insulin 
response to an oral glucose tolerance test were inversely related to birth weight 
(p<0.02). Therefore as before, the metabolic and consequent vascular 
characteristics of the mother may influence fetal gi'owth either indirectly tlu ough 
the initial development of the placental vascular architecture or directly by 
influencing the provision of fetal “building blocks”. (Table 2)
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Direct evidence
• Maternal obesity linlced to increased CHD in adult offspring 
independently of birth weight
• Maternal obesity increases risk for 2 diabetes in adult offspring
• Maternal (but not paternal) obesity accounts for the association 
between birth weight and adult obesity
Indirect evidence
Maternal obesity:
Influences fatty acid compositions in maternal blood and thus 
transfer to fetus. Ultimately, may influence insulin sensitivity in 
neonate
A high saturated fat diet leads to endothelial dysfunction in rat 
offspring
Increases circulating total FFA concentrations, which correlate with 
diastolic blood pressure o f adolescent offspring 
Linlced to increased inflammatory cytokine levels, which may 
adversely progiamme metabolic and neuroendocrine pathways in 
fetus
Linlced to reduced fertility and increased miscaniage rates
Maternal insulin resistance:
Influences fetal body composition
Correlates with maternal blood pressure which in turn has been 
correlated with blood pressure in offspring
Could explain relationship between low birth weight and increased 
CHD risk in mothers since the metabolic syndrome is a key 
factor governing CHD in women
Is enhanced by smoking, which is linked to low birth weights 
Reduces fertility and increases miscarriage rates
Exercise
• Improves fertility and reduces miscarriage rates
• Increased birth weight in trial o f exercise in pregnant women
• Sedentary lifestyle associated with increased risk for low birth weight
babies relative to women who exercise at moderate levels
• Reduces rates of gestational diabetes
Table 2. Direct and indirect evidence supporting a pivotal role for maternal obesity and insulin 
resistance in fetal programming o f  vascular and metabolic disease
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AIMS
As discussed above, there are many common risk factors for atherosclerotic 
coronary heart disease and pre-eclampsia. These factors are believed to exert their 
effect via various mechanisms resulting in the ultimate end-point of endothelial 
activation and dysfunction. Our aim is to take advantage of recent advances in 
non-invasive micro-vascular assessment, using laser Doppler teclmology in order 
to attempt to demonstrate vascular dysfunction within these risk gi'oups and 
potentially, to develop our understanding of the pathophysiological mechanism 
linking risk factors and vascular complications of pregnancy. Therefore we will 
measure basal and stimulated endothelial function in vivo:
• in healthy lean and obese pregnant individuals
• in women with vascular complications of pregnancy such as pre-eclampsia 
and intia-uterine giowth restriction.
• in pregnant women with a pre-existing medical disorder (type 1 diabetes).
• We also will endeavour to assess the effects of pregnancy itself on 
endothelial fimction both in the short term, i.e. 6-12 months post-partum 
and in the long term, i.e. greater than 15 years post partum.
Forearm sldn perfusion is assessed under basal conditions and following multiple 
doses of iontophoretically applied 1% acetylcholine (Ach, endothelium-
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dependent) and 1% sodium nitroprusside (SNP, endothelium-independent) using 
the laser Doppler imager (LDI). As discussed, most studies concerning 
endothelial function in normal and complicated pregnancy have utilised indirect 
or ex-vivo methods, and pre-existing in-vivo techniques are invasive and have 
produced conflicting results. Therefore, the development of this teclmique will 
represent a significant advance in this area. Additionally, we plan to consider 
endothelial fimction in relation to circulating parameters such as cytokines and 
lipoproteins which have been shown to be pertmhed in pre-eclampsia and which 
may contribute to endothelial damage.
The important feature of this proposal is the application of a novel in-vivo 
technique to a new area. If  this technique allows detection of quantifiable 
differences in endothelial function in pre-eclamptic women, then its non-invasive 
and direct nature offer the potential to measur e vascular fimction at differing 
gestations. Tlris flexibility may facilitate better identification of factors associated 
with or responsible for endothelial dysfunction, and as a result lead to a clearer 
understanding of the pathogenesis of pre-eclampsia. It may also present, in the 
longer term, a suitable means of early identification of women at a high risk of 
developing pre-eclampsia, thereby further enabling better research into potential 
therapeutic options.
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C h a p ter  T w o
METHODS
Laser Doppler perfusion imaging 
in conjunction with iontophoresis of vasoactive solutions 
for the assessment of microvascular function in-vivo.
Factors critical to iontophoretic assessment o f  vascular 
reactivity: Variability in drug delivery.
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Introduction
Increasing evidence relates impaired endothelial vasomotor function to coronary 
heart disease Endothelial dysfunction is not limited to the coronary circulation 
but is also detected in the peripheral circulation proportionate to the degree of 
endothelial dysfunction occuning in the coronary arteries Furthermore, 
assessment of endothelial vasomotion in these peripheral arteries has been shown 
to correlate with and relate directly to coronary dysfimction Thus, there is 
considerable interest in non-invasive methods for assessing peripheral vascular 
function. This is particularly relevant in the pregnant woman, with regards to the 
investigation of vascular reactivity in pre-eclampisa, a condition also suggested to 
arise secondary to microvascular dysfunction. Iontophoresis for transdermal 
delivery of the vasodilator agents acetylcholine (ACh) and sodimn nitioprusside 
(SNP) can be used for this purpose. The teclmique is based upon the fact that a 
charged molecule migrates across the sldn under the influence of an applied 
electrical field and ionised drug delivery is dependent on the magnitude of the 
applied current and its duiation (current x time = charge, in Coulombs). In the 
past iontophoresis has been used in conjunction with laser Doppler flowmetry 
(LDF), a non-invasive method for assessing microvascular perfusion at a single 
point More recently, iontophoresis has been combined with laser Doppler 
imaging (LDI) which reduces measuiement variability because, unlike 
LDF, LDI measures perfusion across many points and thus an average measure 
of perfusion can be computed for any chosen area. Iontophoresis of ACh tests 
endothelial fimction since binding to muscarinic receptors with subsequent
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generation of NO requires intact endothelial cells and is therefore said to be 
“endothelium-dependent”. Vasodilatation is ultimately mediated by action of NO 
on vascular smooth muscle (via the cGMP pathway) and so iontophoresis of SNP, 
an NO donor, is used as an “endothelium-independent” control. This methodology 
has been widely used to investigate microvascular function in a vaiiety of disease 
states, most commonly diabetes mellitus where endothelial dysfunction has been 
implied by a decreased response to ACh iontophoresis
Iontophoresis has a number o f attractions. It provides a direct assessment of 
microvascular fimction, is simple to use, and most importantly for clinical 
application, it is non-invasive. However, there are some important factors which 
can influence iontophoretic drag responses and its inteipretation which in the past 
have not been addressed. One of these is the assumption that drug delivery is 
solely influenced by the magnitude of cunent applied and its duration (charge). 
This ignores the fact that the electrical properties of skin differ between subjects 
and this could impact on effective drug delivery. By monitoring the voltage across 
the iontophoresis chambers we investigated for the first time whether variation of 
the electrical properties of skin between normal subjects influences the magnitude 
of the responses to ACh and SNP. The results of these investigations have critical 
implications for futuie clinical studies of endothelial function that employ 
iontophoresis of vasoactive drags.
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Methods
Experiments were performed in twenty healthy subjects aged 22-50 years of both 
sexes with no history of peripheral vascular abnormalities such as Raynauds 
syndrome, dermatological diseases or systemic disease processes such as diabetes 
mellitus and all were non-smokers. All subjects were fasted overnight and asked 
to refrain from diinldng any fluids except water prior to measurements. These 
were undertaken in a temperatui'e controlled room (23 ± UC) and all subjects 
were allowed to acclimatize for 30 minutes prior to measurement. The study was 
performed according to the Declaration of Helsinld, the institutional ethics 
committee approved procedures and informed consent was obtained.
Iontophoresis
Drug delivery was achieved using a battery-powered constant current 
iontophoresis controller (MIC-le; Moor Instruments Ltd, Axminster, UK). The 
chambers used for iontophoresis (ION 6; Moor Instruments Ltd) were constructed 
of Perspex (internal diameter 22mm; area 3.8cm^) with an internal platinum wire 
electrode. Two chambers were attached to the skin of the volar aspect of the 
forearm by means of doubled-sided adliesive disks avoiding hair, broken skin and 
superficial veins. The chambers were connected to the anode and cathode 
connections on the iontophoresis controller. A digital multimeter was connected 
in parallel to monitor voltage across the chambers (Fig 1 and 2). As a constant 
current source was used, resistance values were calculated from the recorded 
voltages using Ohm’s Law.
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IO N T O PH O R E SIS  
CONTROLLER
LASERDOPPLER
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_JDRUGCHAMBERS
PERFUSIONIMAGES
F igure 1 : Laser Doppler Imager and iontophoresis set-up.
Control o f current delivery was programmed into the software for the laser 
Doppler imager such that current was switched on at the beginning o f a scan and 
remained on throughout the scan until the start o f the following scan. The current 
was then either left on for the next scan or was switched o ff once the total charge 
had been delivered. Current duration was determined by the time taken to 
complete each scan (50 seconds) multiplied by the total number o f scans 
programmed. To limit the iontophoresis dose, resulting from relatively long scan 
times, low currents were used: the protocol involved incremental current delivery 
with four scans at 5pA, four at lOpA, four at 15pA and two at 20 |liA  giving a total 
charge o f 8mC ( f ig  3 A ). Each frame is associated with the current delivery during
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that scan, although the resulting vascular response could be delayed due to the 
time required for chemical factors to initiate it.
2.5 ml of 1% acetylcholine cliloride (Sigma) was introduced into the anodal 
chamber whilst 2.5ml of 1% sodium nitropmsside (Sigma) was placed in the 
cathodal chamber, Thus both agents were delivered simultaneously dming each 
period of cuiTent administration. The veliicle for these dmgs was 0.5% NaCl. 
Fluid was prevented from escaping by placing circular 32mm coverslips over the 
chambers.
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Fig 2. A; Diagram o f  the experimental arrangement. Acetylcholine (ACh) was placed in the anodal 
chamber and sodium nitroprusside (SNP) in the cathodal chamber, A digital voltmeter (V) 
was connected between these.
B: The backscattered light intensity provides the Photo image with the Doppler shifted 
component providing the Flux image. This scan was taken at the conclusion o f  the 
administration o f  current. Flux is colour-coded with lowest perfusion dark blue (0 PU) and 
highest in dark red (500 PU).
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Perfusion measurements
Non-invasive measmement of skin perfusion was performed by means of a laser 
Doppler imager (Moor Instruments Ltd, Axminster, UK) equipped with a red 
laser (wavelength 633mii; power IniW; beam diameter 1mm). The technique is 
based upon the Doppler shift imparted by moving blood cells in the underlying 
tissue to the backscattered light. The laser is scanned in a raster fashion over both 
chambers and through the coverslips. The backscattered light is collected by 
photodetectors and converted into a signal proportional to perfusion in arbitrary 
perfusion (flux) units (PU) that is displayed as a colour-coded image on a monitor 
(fig 2B). Perfusion measurements were obtained using the imager manufacturer’s 
image analysis software by outlining a region of interest (ROI) around the internal 
circumference of the chamber. Statistical analysis of the ROI was subsequently 
performed offline to yield the median flux value across approximately 700 
measiuement points. Twenty repetitive scans were taken, the first being a control 
(pre current administration) followed by the incremental current protocol 
described above (14 scans) followed by five further scans with no current 
administration. The biological zero was measured by taking a single scan after 
occluding the arterial blood supply with a sphyngomanometer cuff. This was 
found to be consistent between and within subjects with a mean (± SEM) of 23.9 
± 0.72 PU.
To determine whether the combination of fluid in the iontophoresis chambers and 
the coverslip affect the flux signal, scans were obtained comparing basal
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perfusion in the anodal chamber (containing ACh) and in the cathodal chamber 
(containing SNP) to that occurring in a surrounding area of skin. The latter 
showed significantly (P = 0.011, 1-way ANOVA; n = 14) higher basal perfusion 
(71.6 ± 6.4 PU; mean ± SEM) compared to the values at the ACh-containing 
chamber (54.4 ± 2.7 PU) and the SNP-containing chamber (53.9 ±3.7  PU), 
indicating that the chambers produce some attenuation of the LDI signal, but there 
was no difference between chambers. Although some signal attenuation occurs, 
perfusion changes in response to intei'vention are unaffected. Following 
occlusion of the blood supply to the arm, the ratio of the increase in perfusion 
from biological zero showed no significant differences between the anodal and 
cathodal chambers and adjacent skin (1.93 ± 0.09, 2.23 ±0.15 and 2.18 ± 0.16 
respectively; P = 0.26).
Drugs
In separate experiments, seven subjects were administered 600mg aspirin orally 
half an horn* prior to iontophoresis in order to inlhbit prostaglandin synthesis. This 
has been shown to be an adequate period of time to produce maximal inhibition of 
endothelium-derived prostacyclin Aspirin was dissolved in orange juice to 
disguise its taste, which allowed use of plain orange juice as a placebo. 
Measurements with placebo or aspirin were performed on one occasion each, 
separated by a minimum of 14 days. The investigators were aware of the status of 
the subjects, ie not blinded.
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Fig 3.A: Scans taken with SNP in the upper chamber and ACh in the lower chamber. The
differences in the tim e courses o f  the drug-induced vasodilator responses are clear. The 
numbers in each frame refer to the applied current (in pA).
B: Repetitive scans in a single subject with 0.5% NaCl vehicle. Each scan duration was 50s 
with no delay between scans.
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Statistical analyses
Measui ement of responses was performed using raw values but in some cases an 
assessment of the overall response to dmgs was obtained by taking the area under 
the perfusion.time curve. For resistance data, resistance.time integrals were 
computed. Comparisons were by ANOVA or Student t-tests, paired or unpaired as 
appropriate. All tests were two-tailed and data are expressed as means ± SEM or 
± SD. Because of the marked differences in variances between basal perfusion 
values and the maximal responses to the drugs, but the similar coefficients of 
variation, logio transformation of the data was performed to equalize the variances 
and thereby permit parametric data analysis. The variance ratio, comparing 
maximal dmg responses to the control (pre current application) scan, was found to 
vary between 9-60 for the raw perfusion data but after log transformation the 
same variance ratio range was reduced to 0.7-1.2.
Results
Responses to ACh and SNP
Iontophoresis of ACh and SNP resulted in progressive increase in perfusion, 
although with differing timecouises (fig 3A). ACh showed a more rapid onset 
than SNP but also a rapid decline once cmTcnt was terminated. This rapid fall in 
the ACh response may be due to the presence of acetylcholinesterase in human 
blood vessels Current administration with only vehicle present failed to elicit 
vascular responses (fig 3B). The time course of the responses to both drugs for 
seven subjects is shown fig 4A. The dmg responses differed significantly
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(P<0.001; 2-way ANOVA) but it is clear that the current protocol used did not 
elicit hyperaemic responses with only the vehicle present. With responses 
expressed relative to cumulative charge, both ACh and SNP reached a plateau by 
the time about half the charge was delivered (fig 4B).
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Fig 4.A: Time course o f the response to iontophoretic administration o f ACh (v) and SNP (□) 
dissolved in 0.5% NaCl as well as the response to this vehicle at the anode (v) and cathode (□). 
Dose dependent increase in perfusion is significant (P<0.0001, 1-way ANOVA) for drugs but not 
for vehicle. Mean ± SEM; n = 7 subjects.
Fig 4 B: Same perfusion data as in A, but plotted against cumulative charge.
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A striking observation is that drug delivery is not only influenced by the applied 
charge but also by the electrical resistance o f  the skin which varied in different 
subjects (fig 5).
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Fig 5. Relationship between perfusion.time integrals and the resistance.time integrals for the 
response to ACh in a series o f subjects. The inverse nature of the relationship is clear.
There is an inverse linear relationship between the perfusion integral and the 
resistance integral for both ACh (fig 6A; r =  -0.86) and SNP (fig 6B; r = -0.96) 
i.e. higher resistance is associated with smaller vasodilator responses for both 
drugs and vice versa. These relationships were significant, P < 0.0001 in both 
cases. Correcting for this variable, by dividing by the integral o f  conductance (the 
reciprocal o f  resistance) over time or more simply by multiplying individual 
perfusion values by the integral o f  resistance over time, normalises responses.
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Correlating these corrected perfusion integrals to their respective resistance 
integrals now yields non-significant /  values of 0.011 for ACh and 0.025 for SNP 
(fig 6C, D), indicating the effectiveness of this correction and lowering apparent 
inter-subject variability. The coefficient of variation for the log perfusion integral 
of ACh was 3.36% (n = 7) prior to correction for resistance and 1.86% thereafter. 
The respective coefficients for SNP were 2.18% and 1.56% respectively. These 
corrections reduce variability between subjects by about a half and a third 
respectively. The between-day coefficient of variation of the ACh response for the 
same four subjects described in methods after correction for resistance was 3.04 ± 
0.67% (mean ± SD), which was about half of the imcorrected value.
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FIg 6 A: Relationship between the log transformed perfusion.time integral and the resistance.time 
integral for ACh.
B: Relationship between the log transformed perfusion .time integral and the resistance.time 
integral for SNP. n =  \ 4 and P<0.0001 for both A and B,
C: Correction of log transformed perfusion.time integral (multiplying flux by the 
resistance.time integral) for ACh and plotting against the resistance.time integral no longer 
yields a significant correlation.
D: Similarly, the corrected data for SNP no longer shows a correlation.
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Influence o f  prostaglandins on cutaneous vascidar responses 
The vascular responses to both ACh and SNP appeared to be significantly 
depressed after administration of aspirin (P<0.0001; 2-way ANOVA; fig 7 A & 
B). However, it was found that resistance during ACh and SNP administration 
was significantly greater (P = 0.03; Student paired t test, n = l \  means ± SD) after 
aspirin (6.25 ± 2.08 MQ min) than with placebo administration (4.09 ± 1.04 MQ 
min). After correcting for resistance, there was no longer any significant 
difference between the responses for either ACh or SNP (P = 0.64 and P  = 0.75 
respectively, 2-way ANOVA; fig 7 C & D). Measui’ement of drug responses in 
four subjects on two separate days but without aspirin administration showed no 
significant differences in resistance between days (4.32 ± 0.94 and 4.74 ± 0.6 
MQ min).
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Fig 7. Vascular responses to administration o f  ACh (A) and SNP (B) in 0.5% NaCl vehicle before 
(open symbols) and following (closed symbols) administration o f aspirin. For both ACh and SNP 
the responses before and after administration o f aspirin differ significantly (P<0.0001, 2-way 
ANOVA). Vascular response to administration o f ACh (C) and SNP (D) before (open symbols) 
and following (closed symbols) administration o f aspirin after correcting flux values for resistance 
in each subject. Mean ± SEM; n = 7 subjects.
Discussion
There is mounting interest in the measurement o f  vascular function in 
cardiovascular research since endothelial dysfunction may be an early feature o f  
the atherogenic process and is amenable to therapeutic intervention. It can be 
argued that endothelial function integrates the stress o f  other risk factors. These 
observations may be extrapolated to cardiovascular com plications o f  pregnancy
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such as pre-eclampsia. Laser Doppler imaging with iontophoresis is the most 
recent teclmique used for assessment of endothelial fimction and is particularly 
attractive because of its non-invasive nature. Although iontophoresis only 
assesses the cutaneous microcirculation, this is effectively a robust surrogate 
marker of vascular fimction in other vascular beds. Reduced responsiveness to 
iontophoretic administration of ACh has been observed in diabetes and
hypercholesterolaemia and in both these conditions there is a parallel 
reduction of the ACh response in the forearm circulation (predominantly a 
skeletal muscle vascular bed) assessed by venous occlusion plethysmography 
Moreover, attenuated response in the skin of heart transplant patients to ACh 
iontophoresis is paralleled by reduced responsiveness of coronary blood 
vessels to ACh in this group In addition, ACh-induced vasodilatation is 
reduced in both the foreami musculature and skin in patients with essential 
hypertension. Thus, many conditions affecting the cardiovascular system appear 
to result in global endothelial dysfunction and therefore assessment of the 
cutaneous micro circulation yields valuable insights into peripheral vaseular 
function.
The current protocol used in the present study resulted in a overall lower charge 
(8mC) than that used in previous studies and this, combined with a large 
surface area for iontophoresis and the use of a weak saline vehicle prevented the 
development of hyperaemic artefacts at the cathode. This obviated the need to use 
a topical anaesthetic such as EMLA® cream which produces cutaneous
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vasoconstriction presenting a problem as any vasodilator responses would 
then be superimposed upon a basal vasoconstrictor tone. In preliminary 
experiments we have observed that iontophoresis of ACh and SNP to EMLA- 
treated skin elicited substantially reduced vasodilator responses (by 30-50%, 
unpublished observations) using the protocol employed in the present 
investigation.
Past work aimed at establishing the role of prostaglandins in mediating the 
response to ACh has produced contradictory results. It was previously obseiTed 
that the vasodilator response to iontophoresis of ACh was reduced by 
administration of oral or intravenous aspirin However, Morris & Shore 
found no difference in the ACh response after oral aspirin. Our finding of an 
apparent difference in the vascular responses to both ACh and SNP after oral 
aspirin suggests a possible explanation for discrepancies between these earlier 
studies. After correction for resistance, there was no longer any difference in the 
ACh and SNP responses and this may indicate that variations in resistance across 
the iontophoresis circuit during drug administration could have been a 
confounding factor in previous studies. Aspirin itself could have changed skin 
resistance, and the time control experiment supports this as no change in 
resistance was found when measui'ed on separate days but without aspirin 
administration. The change in resistance could not be ascribed to variations in 
room temperatui'e, as all measurements were undertaken in a temperature- 
controlled room and subjects allowed to acclimatize. It is therefore possible that
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in previous studies, variations in skin resistance might have influenced effective 
drug delivery leading to differing results. This emphasizes the importance of 
correcting for resistance to avoid potentially spurious results, particularly if 
measurements are taken at different sites or on different days.
The variation in calculated resistance between subjects suggests that there may be 
variable numbers of resistance pathways in the sldn of different subjects. As the 
equipment and the composition of the solutions used was the same between 
subjects, the site of the resistance must be related to the skin. It might be the case 
that lower resistance is associated with a gr eater number of low resistance 
pathways, such as sweat ducts or hair follicles, being available and these 
pathways are close to blood vessels. This is quite likely given that sweat glands 
and their associated ducts, as well as hair follicles, are Imown to be richly 
vascularized Higher resistance may be associated with high resistance 
pathways for ion flow, mostly likely tlirough the stratum corneum, and these are 
more remote froru blood vessels. Thus, effective drug delivery could differ even 
though the charge remains constant. In effect, although the same total amount of 
drug may be delivered, the vascular response could differ depending on the 
relative number of low resistance pathways available. The inverse relationship 
between drug response and resistance, with calculated resistance integi’als 
showing on average over twofold variation between subjects, indicates that skin 
resistance may contribute to inter-subject variability of drug responses. This has 
important implications for inteipreting responses to drug administration in clinical
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studies. This factor has not been taken into account in any previous study using 
iontophoresis and variations in observed responses between subject groups could 
have been influenced by a systematic variation in resistance rather than a true 
difference in vascular reactivity. Tlris said, it remains likely that diabetic patients 
do have vascular dysfunction as most studies using venous occlusion 
plethysmography and intra-aiterial drug administration show a reduced response 
to ACh compared to control subjects However, observed differences to
iontophoresis of drugs at different sites could be explained by variations in skin 
resistance. Reduced vascular responses have been observed in the skin over the 
dorsum of the foot compared to the forearm for both normal and diabetic 
subjects Similarly, marked differences in response to iontophoretic 
administration of ACh occurs at various sites on the hand and forearm in normal 
subjects assessed by using laser Doppler flowmetry. Even when LDI is used, 
between-site variation in the magnitude of responses occur, although variability 
can be reduced by ensuiing that consecutive measurements are taken from the 
same site This reinforces the need to monitor voltage during iontophoresis so 
that resistance can be estimated. Only by doing this is it possible to acerbately 
assess the extent to which effective dmg delivery is affected by skin resistance 
and to correct for this variable.
In conclusion therefore, these investigations have shown for the first time that 
resistance is an important but previously unrecognised variable influencing 
iontophoresis. The inverse relationship between skin resistance and blood flow
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responses to both ACh and SNP indicates that resistance influences effective drug 
delivery. We anticipate that correction for resistance, coupled with use of 
appropriate vehicles, chambers and iontophoresis protocols, will lead to 
significant improvement of the iontophoresis technique and permit its additional 
development, thereby fiu’ther increasing its robust nature as a non-invasive tool 
for assessment of endothelial function in clinical studies.
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C h a p ter  T h ree
METHODS
Laser Doppler perfusion imaging 
in conjunction with iontophoresis of vasoactive solutions 
for the assessment of microvascular function in-vivo.
Factors critical to iontophoretic assessment o f vascular 
reactivity: Elimination o f electrically-induced
artefacts.
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Introduction
The technique of iontophoresis is based upon the fact that a charged molecule 
migmtes across the skin under the influence of an applied electrical field and 
ionised drug delivery is dependent on the magnitude of the applied current and its 
duration (current x time = charge, in Coulombs). Iontophoresis of acetylcholine 
(ACh) takes place at the anode as this compound is positively charged in solution. 
Therefore the "like" charge repels the ions and enables their absorption into the 
skin. Likewise for sodium nitroprusside (SNP), this compound is delivered at the 
cathode and negatively charged in solution. However, application of electrical 
charge at the cathode with only the vehicle for SNP present (distilled H2O) can 
produce an electrically induced hyperaemic response sometimes referred to 
as a “galvanic” response. This artefact was also observed by Grossmann et al 
at both the anode and cathode in response to iontophoresis of a variety of cations 
and anions respectively, although the control experiment of applying the same 
current protocol with only the vehicle (propylene glycol) present was not 
performed.
Mechanisms underlying electrically-induced hyperaemia are still poorly 
understood. Prostaglandins have been implicated, as aspirin, a prostaglandin 
synthase inliibitor, can produce inliibition although only at the cathode 
Wliatever the mediators, there are a number of factors which may influence the 
development of this artefact such as pH changes at the electrodes, skin resistance, 
the nature of the solution in the chamber and the chamber size itself. The aim of
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this investigation was to examine conditions under which electrically-induced 
hyperaemia is generated and whether it can be eliminated. We hypothesized that 
the electrical properties of the solution used for delivery of the drugs might 
influence the development of such hyperaemia, which could be minimised by 
changing the composition of the drug vehicle. Sub-hypotheses included whether 
factors such as chamber size, pH changes at the electrodes and skin thiclaiess 
might influence the development of these artefacts. The contribution of 
prostaglandins to these responses was also investigated. The results of this 
investigation have implications for future clinical studies of endothelial function 
that employ iontophoresis of vasoactive drugs.
M aterials and M ethods
Experiments were performed in twenty healthy subjects aged 22-50 years of both 
sexes with no history of peripheral vascular abnormalities such as Raynauds 
syndrome, deiinatological diseases or systemic disease processes such as diabetes 
mellitus. The institutional ethics committee approved all procedures and informed 
consent was obtained. Subjects were fasted prior to measurement and were either 
life-long non-smokers or had no recent history (within 1 year) of smoking. 
Measurements were performed with the subjects supine in a quiet room with an 
ambient temperature of 22 ± LC.
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Iontophoresis protocols
Drug delivery was achieved as described in chapter one, using a battery-powered 
constant current iontophoresis controller (MIC-le; Moor Instruments Ltd, 
Axminster, UK). To assess the effect on hyperaemic responses of chamber size, 
two chambers with internal diameters of 22mm, area 3.8cm^ and 10mm, area 
0.78cm^ were used for iontophoresis. Chambers were applied as previously 
described in chapter one. Sldn temperature close to the iontophoresis chambers 
was monitored continuously tlii'oughout.
2.5 ml of 1% acetylcholine chloride (Sigma) was introduced into the anodal 
chamber whilst 2.5ml of 1% sodium nitroprusside (Sigma) was placed in the 
cathodal chamber. Thus both agents were delivered simultaneously during each 
period of crurent administration. The vehicle for these drugs was either distilled 
H2O or saline solutions. These solutions were prevented from escaping from the 
chambers by placing circular 32mm coverslips over the chambers. In four subjects 
the electrical resistance of the skin within the chamber was increased by applying 
Vaseline thinly over the skin surface and then current was applied with 0.5%
NaCl alone in the chambers.
CiuTcnt delivery was achieved as described previously. Two protocols were used 
in the present experiments:
74
(i) An incremental protocol involving stepped current delivery with four 
scans at 5pA, four at lOpA, four at 15pA and two at 20pA giving a total charge 
of 8mC over 11.7min. This was intended to minimise electrically-induced 
hyperaemic artefacts with the relatively large surface area and low currents 
yielding a cumulative charge density of only 2.1mC/cm^.
(ii) A ‘galvanic’ protocol, consisting of tlnee consecutive periods of current at 
lOOpA giving a total charge of 15mC over 2.5min, was employed with the 
specific purpose of eliciting electric ally-induced cutaneous hyperaemia as this 
gives a cumulative charge density of 3.95mC/cm^, almost double that in the 
incremental protocol.
Vehicles
The drug vehicles used were either distilled water, or 0.5%, 1% or 5.8% saline 
solutions (5.8% -  IM  NaCl). The numbers of subjects in whom these were used 
are given in the text and figure legends.
Perfusion measurements
Non-invasive measurement of skin perfusion was performed as described in 
chapter one. Twenty repetitive scans were taken, the first being a conti'ol (pre 
current administration) followed by the incremental current protocol described 
above (14 scans) followed by five finther scans with no current administration. 
For the ‘galvanic’ protocol, after a control scan three scans were administered
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during which the lOOpA current was passed followed by a further 16 scans 
without cuiTent.
Drugs
In separate experiments, seven subjects were administered 600mg aspirin orally 
half an hour prior to iontophoresis in order to inliibit prostaglandin synthesis. This 
has been shown to be an adequate period of time to produce maximal inliibition of 
endothelium-derived prostacyclin Aspirin was dissolved in orange juice to 
disguise its taste, which allowed use of plain (aspirin-free) orange juice as a 
placebo. Using the ‘galvanic’ protocol, measurements were performed 
sequentially, one on each arm, before and after aspirin in a single blind fashion, 
with the two measurements being separated by less than one hour". The 
investigators were aware o f the status of the subjects, ie not blinded.
p H  measurements
As it has been shown that pH changes can occur at sites of iontophoretic current 
administration in five subjects the fluid from each chamber was removed after 
the incremental iontophoresis protocol and its pH measured. Tliis was preceded 
by measurement of the pH of fluid left in the chambers for the same duration as 
the iontophoresis protocol, but without applying any current.
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Skin thickness measurement
It is well loiown that skin thiclcness is quite variable between subjects, but 
whether this influences iontophoresis of drugs or the apparent electrical properties 
of sldn is imlcnown. We used callipers (Ki'oeplin Oddest OD 1020T10, Germany; 
resolution 0.01mm) to measure skin thiclaiess at the anodal site in a series of 
subjects prior to iontophoresis.
Statistical analyses
Statistical analyses, variance ratios and coefficients of variation are described in 
chapter one
Results
Electrically-induced hyperaemia
Using the distilled HgO vehicle alone, it was apparent that in about 75% of 
subjects a hyperaemic response developed at the cathode during incremental 
current administration and gradually increased (fig lA). This response clearly 
overlaps with the response to iontophoresis of SNP that typically tends to plateau 
towards the end of the scan period (fig IB). In general, the electrically-induced 
artefact was less of a problem with respect to the ACh response as this response 
was only obseiwed at the anode in one out of twenty subjects using this current 
protocol. No significant temperature change occurred between the beginning and 
end of perfusion measur ements, indicating stable conditions.
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Fig l.A : Repetitive scans in a single subject taken using the incremental current protocol (see 
M ethods) with distilled H^O vehicle alone. Scan duration was 50s with no delay between scans. 
Electrically-induced hyperaemia develops at the cathode towards the end o f  the period o f  current 
administration.
Fig l.B ; Scans taken from the same subject using the incremental current protocol with SNP in the 
upper chamber and ACh in the lower chamber. The differences in the tim e courses o f  the 
vasodilator responses to ACh and SNP are clear. The numbers in each frame refer to the applied 
current (in piA).
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0.5% saline vehicle
Use of distilled water as the vehicle resulted in higher voltages than when using 
the 0.5% saline vehicle (fig 2). However, comparison of the perfusion integi'als 
indicated that there was no significant difference for either the ACh or SNP 
responses irrespective of whether these dmgs were dissolved in water or 0.5% 
NaCl vehicles (fig 3). Furthermore, the time course and magnitude of the 
responses to ACh and SNP were the same irrespective of the vehicle used (fig 4A 
cf 4B) but the development of electrically-induced hyperaemia is obvious when 
current was passed using the water vehicle alone (fig 4A) compared to the 0.5% 
saline vehicle (fig 4B).
79
10
8
6
4
2
0
0 5 5 5 5 10 10 10 10 15 15 15 15 20 20 0 0 0 0 0
Current (nA)
B
g
S5,!2
2 0.5a:
0.0
5 5 5 5 10 10 10 10 15 15 15 15 20 20
10
8
6
4
2
0
0 5 5 5 5 10 10 10 10 15 15 15 15 20 20 0 0 0 0 0
Current (nA)
D
I
0.0
5 5 5 5 10 10 10 10 15 15 15 15 20 20
Current (pA) C u rre n t (nA)
Fig 2. A: Voltage recorded across iontophoresis chambers during current delivery with HiO
vehicle (O) and drugs dissolved in vehicle ( • ) .  These differ significantly (P<0.001, 2-way 
ANOVA) and current-induced increase in voltage is significant in both cases (P<0.0001, 
repeated measures I-way ANOVA).
B: Resistance calculated from voltages recorded in A for HiO vehicle (O) and drugs 
dissolved in vehicle (■). These differ significantly (P<0.001, 2-way ANOVA) and 
progressive fall in resistance with increasing current is significant in both cases (P<0.0001, 
repeated measures 1-way ANOVA).
C: Voltage recorded across the iontophoresis chambers during current delivery with 0.5% 
NaCl vehicle (O) and drugs dissolved in this vehicle ( • ) .
D: Resistance calculated from voltages recorded in C for 0.5% NaCl vehicle (O) and drugs 
dissolved in vehicle (■). Mean ± SEM; data from seven subjects for all groups. No 
significant differences between 0.5% NaCl vehicle and drugs dissolved in this vehicle for 
either C or D.
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Fig 3. A: Comparison of voltage.time integrals for H2 O and the different concentrations o f saline 
vehicles. Open columns represent values for drugs dissolved in H2 O and 0.5% saline. n = 5- 
14 subjects. Water vehicle differs significantly from all saline vehicles (P<0.05; Scheffe F- 
test), but saline vehicles do not differ from each other.
B: Log perfusion voltage.time integrals showing no difference in the magnitude o f the 
responses o f ACh and SNP in H2 O and 0.5% NaCl vehicles. Mean ± SEM; /7 = 7 subjects 
for each group in both A and B.
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The relevance of monitoring voltage becomes apparent when examining the 
development of the electrically-induced hyperaemic response. For individual 
subjects, talcing the integral of voltage over time for different vehicles and 
plotting these against the perfusion values at the cathode for scan 20 reveals that 
there is a threshold voltage integral beyond which hyperaemic responses are 
triggered (fig 5). It is noticeable that none of the saline vehicles (0.5%, 1% and 
5.8% NaCl) was associated with an electrically-induced hyperaemic response 
(defined as a flux reading >100 PU) whereas the water vehicle is associated with 
these hyperaemic responses in all but two cases and in both of the latter the 
voltage integrals were the lowest for this group. However, when skin resistance 
was increased by Vaseline, even with the 0.5% saline vehicle higher voltages 
occurred and hyperaemic responses were generated. Also noticeable was the 
absence of a consistent relationship between the voltage integral and the 
magnitude of the hyperaemic response, perhaps indicative of varying magnitudes 
of responsiveness in different subjects.
82
3.0 1
T  2.0 -
ILO)
0 5 5 5 5 10 10 10 10 15 15 15 15 20 20 0 0 0 0 0
Current  (^A)
B
3.0
2.5
DQl
2.0
0 5 5 5 5 10 10 10 10 15 15 15 15 20 20 0 0 0 0 0
Current  (^A)
Fig 4. A: Time course o f the response to iontophoretic administration o f ACh (■) and SNP (□ )  
dissolved in H2 O as well as the response to this vehicle at the anode ( • )  and cathode (O ). 
Dose dependent increase in perfusion is significant (P<0.0001, 1-way ANOVA) for all 
except for water vehicle in the anodal chamber.
B: Time course o f the response to iontophoretic administration o f ACh (■) and SNP (□ )  
dissolved in 0.5% NaCl as well as the response to this vehicle at the anode ( • )  and cathode 
(O ). Dose dependent increase in perfusion is significant (P<0.0001, 1-way ANOVA) for 
drugs but not for vehicle. Mean ± SEM; « = 7 subjects for both A and B.
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Fig 5. Analysis o f flux responses (at scan 20) occurring during incremental current 
administration using water ( • ;  n =  14), 0.5% NaCl (A; n = 8), 1% NaCl (□ ; n =  5) and 5.8% NaCl 
(0; n =  6) NaCl vehicles plotted against voltage.time integral (area under the curve - AUC) for 
each vehicle. Also plotted are values for the 0.5% NaCl vehicle in chambers where Vaseline was 
applied to the skin (O ; n = 4).
pH  measurements
Distilled H2O (pH 7) instilled in both chambers and left in contact with skin for 
the duration o f  the incremental current protocol (16.7 min), but without 
application o f  current, resulted in a significant (P<0.01 ; n = 5) reduction in pH at 
both the anodal (5.9 ± 0.33) and cathodal (5.96 ±  0.33) chambers (mean ±  SEM). 
However, following current application, chamber fluid pH was not found to have 
changed significantly at either the anodal (5.72 ±  0.37) or cathodal (6.02 ±  0.26)
84
chambers. Comparison of the anodal and cathodal chambers showed no 
significant difference either prior to (P=0.9) or after (P=0.52) current 
administration. Unsiuprisingly, there was no pH difference between anodal and 
cathodal chambers with ACh and SNP in either water or 0.5% NaCl veliicles.
Chamber size
Another factor which could influence the electrically-induced hyperaemic 
response is the size of the iontophoresis chamber. Using the incremental protocol, 
and water as the vehicle, employing a smaller chamber (as described in methods) 
resulted in higher voltage integi’als and almost tripled the perfusion integral of the 
electrically-induced hyperaemic response at the cathode (3546 ± 1277 PU min) 
compared to that obtained using the large chamber (1360 ± 823 PU min), this 
difference being significant (P = 0.005; n = 4; paired t-test; means ± SD). This 
difference is likely to arise due to the difference in charge density (2. Im C /cnf 
and 10.2mC/cm^ respectively). The smaller chamber also showed an earlier 
response onset and hyperaemia spreading well beyond the chamber. Additionally, 
use of the smaller chamber resulted in hyperaemic responses occurring at the 
anode in three out of four subjects.
Effect o f  skin thiclcness on resistance and vascular responses
It was noticeable that dui'ing current delivery using the incremental protocol, the 
calculated resistance values varied between subjects. To establish whether this
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was a consequence of variations in sldn thiclcness, sldn fold thiclaiess at the 
anodal site was measured using callipers in each subject prior to current 
administration. No significant correlation between calculated resistance and sldn 
fold thiclaiess was found (r  ^= 0.0002; P = 0.96; n == 9), indicating that 
subcutaneous fat does not affect resistance. In addition, no significant correlation 
was observed between skin fold thiclcness and the ACh perfusion.time integi'al (r  ^
= 0.13; P = 0.38; 11 = 8).
Prostaglandin dependence o f electrically-induced hyperaemia
To establish whether prostaglandins mediate electrically-induced hyperaemia, the 
effect of oral aspirin administration on the electrically-induced response was 
investigated. The ‘galvanic’ protocol elicited hyperaemic responses at the cathode 
in all subjects tested {n = 7) and at the anode in some {n = 3) and these were both 
strongly inhibited by aspirin {P < 0.001 in both cases; 2-way ANOVA; u = 7; fig 
6). Resistance integrals before (0.38 ± 0.05 MO min) and after (0.39 ± 0.05 MO 
min) aspirin did not differ significantly (P = 0.76, Students paired t test; means ± 
SD).
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Fig 6. A: Response at the cathode to application of three 50s periods o f current (black bar) at 
lOOf-iA using the galvanic protocol with the distilled water vehicle before (O ) and 
following ( • )  administration o f aspirin.
B: Response to the same current protocol and water vehicle at the anode before (O ) and 
following ( • )  administration o f 600mg aspirin. Mean ± SEM; n = 7 subjects. Responses 
before and after aspirin differ significantly (P<0.001, 2-way ANOVA) in both cases.
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Discussion
The aim of this investigation was to monitor voltage changes associated with the 
application of constant current dming iontophoresis, in order to understand better 
the generation of hyperaemic artefacts associated with this procedure. Another 
aim was to establish whether such hyperaemic responses could be attenuated 
using a 0.5% NaCl vehicle rather than distilled water.
Administration of incremental current in the presence of the water vehicle 
resulted in the development of a hyperaemic response, most obvious at the 
cathode, which is in agreement with previous investigations The finding
that a tlneshold voltage.time integral had to be exceeded before such a 
hyperaemic response was triggered (fig 5) clearly indicates that it is not simply 
the total charge that detennines this response. The same total charge (8mC) failed 
to elicit cathodal hyperaemia using the 5.8%, 1% and 0.5% saline vehicles but did 
so with the water vehicle, the only apparent difference being the voltage integr als, 
implying this may be an important parameter in the generation of such artefacts. 
The finding that increasing epidermal resistance by topical application of Vaseline 
resulted in higher voltage integi'als and hyperaemic responses, even when 
employing the 0.5% NaCl vehicle, further supports this. There was no obvious 
relationship between the magnitude of the hyperaemic response and voltage.time 
integi'al of individual subjects. It is possible that there is a particular tlrreshold 
beyond which hyperaemia is triggered, but the magnitude of this response need 
not be correlated with the voltage.time integi'al. This would be consistent with the
observation that the magnitude of ‘axon reflex’ flares to identical stimuli shows 
substantial variability between individual subjects The fact that the voltage 
profile for the water vehicle differed markedly from that occurring with the drug 
solutions questions the appropriateness of examining ‘control’ responses using 
only the drug vehicle whose electrical resistivity may be quite different compared 
to the solutions containing ACh and SNP.
Although it has been shown previously that water iontophoresis results in pH 
changes at both anode and cathode the charge used with the incremental 
protocol in the present study was substantially lower and did not result in pH 
changes at the chambers even though hyperaemic responses still occurred. This 
indicates that cathodal hyperaemia induced by electrical stimulation is not 
mediated by hydroxyl (OH") ions. Again, the voltage.time integral is the only 
factor linking to electrically-induced hyperaemic responses. However, as pH 
changes were not measui ed in the skin itself, an effect due to changes in 
subdennal H^ or OH" concentrations cannot be excluded by this study.
Use of a saline vehicle virtually eliminated the electrically-induced hyperaemic 
artefact and was associated with voltage.time integrals being below the threshold 
for triggering this response. Tliis is achieved by the presence of ions in solution 
resulting in a lowered resistance within the circuit. This concurs with previous 
work that showed electrically-induced hyperaemia to be greatly attenuated using a 
hyperosmolar (5M) solution of NaCl Tliis work also showed a reduction in the
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applied voltage with the hyperosmolar solution compared to water, but this was 
only measured for a single current pulse application and not across a range of 
currents as in the present investigation. The main problem associated with use of a 
hyperosmolar vehicle is that the response to iontophoresis of ACh using this 
vehicle was attenuated and both intra- and inter-individual variations were 
increased This may be related to competition between the drug and vehicle 
ions during iontophoresis, paiticularly if there is a major disparity in 
concentration between ionic species. Increasing the ACh concentration lowered 
variability but did not increase the response In the present investigation the 
magnitude of the ACh and SNP vascular responses were unaffected when the 
0.5% NaCl vehicle was used compared to the water vehicle (fig 3B, fig 4 A,B). 
The fact that the vasodilator responses to ACh and SNP were unaffected by the 
presence ofNa"*" and C f ions respectively in the vehicle, and that the latter ions 
had no effect on their own (fig 4B), indicates they cannot contribute to the 
vasodilator responses of ACh and SNP, This implies that sufficient drug gained 
access to elicit vasodilatation, despite the presence of other ionic species. It must 
therefore be the case that there is sufficient charge to cai'ry both drug ions and salt 
ions into the sldn without significant competition, as long as the salt solution is 
relatively low in concentration. The present experiments were limited to the use 
of ACh and SNP as these are the most commonly used agents in studies 
employing iontophoresis, but it is likely that similar principles would apply if 
other ionised dmgs were to be used. Also, the make of manufacture of the 
equipment should not introduce variability, as long as a constant current delivery
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system is used, large diameter chambers employed and the voltage monitoring 
device has a higli input impedance.
In the present investigation, a low concentration of NaCl (0.5%) was used in the 
vehicle and this successfully eliminated the electrically-induced hyperaemic 
response. However, this disagr ees with a previous study where such responses 
occurred using 0.9% NaCl Our results suggest that the differences arise 
because of differences in the chamber sizes and the currents employed. We have 
shown that use of a smaller chamber (0.78cm^), similar to that used in previous 
studies is assoeiated with higher voltages and gieater electrically-induced
hyperaemic responses compared to the responses with the larger (3.8cnf) 
chambers. This is explained by greater current density occuning within the 
smaller chamber and, as all previous studies appeared to have used such 
chambers, this could account for the occurrence of electrically-induced 
hyperaemia even with 0.9% NaCl. Noon et al previously proposed that use o f a 
2% methylcellulose vehicle eliminates the electrically-induced hyperaemic 
response, but we have been unable to confirm this finding. Hyperaemic responses 
still occurred when using 2% methylcellulose despite the total charge used in our 
protocol (8mC) being half that used by Noon et al
The mechanism underlying the electrically-induced hyperaemic response in skin 
remains poorly understood. One hypothesis suggests this response is achieved by 
generation of an “axon reflex” via activation of mechano-insensitive C-
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nociceptors as application of a topical anaesthetic (EMLA® cream) resulted in 
its elimination. (See chapter one) However, application of EMLA cream results in 
cutaneous vasoconstriction and this presents a problem as any vasodilator 
responses are then superimposed upon an artificially-induced vasoconshictor 
tone. An additional complication is that local anaesthetics can also significantly 
alter ionic fluxes across membranes of many cell types, potentially blunting 
endothelial responses to applied drugs. Wliatever the actual mechanism, 
electrically-induced hyperaemia appears to be mediated by prostaglandins as 
aspirin strongly inliibited this response at both cathode and anode, implying that 
similar mechanisms are involved in the generation of this response at both sites. 
This observation is at variance with a previous investigation where aspirin 
substantially reduced cathodal hyperaemia but showed no significant effect on the 
anodal response This discrepancy may be related to differences in the 
experimental conditions between the studies.
In previous investigations there has been some disagi'eement over whether 
vasodilatation in response to iontophoretic adminishation of ACh is prostaglandin 
dependent as two studies found that aspirin administration reduced the magnitude 
of the ACh-induced response but in another study aspirin was shown to
have no effect The fact that electrically-induced hyperaemia can occur at the 
anode, the site of delivery of ACh, and that such artefacts are reduced by aspirin 
administration (fig 6) suggests that in some of these earlier investigations the ACh 
response might have been “contaminated” by this artefact. As different current
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protocols were used in these studies and as the chamber (drug delivery) areas also 
differed (0.5 -  0.78cm^) it is not possible to compare them directly. Monitoring of 
the voltage across the circuit could provide one means of comparison between 
studies if, as the present investigation indicates, electrically-induced artefacts are 
mostly influenced by the voltage.time integi'al as a consequence of circuit 
resistance. This resistance arises partly due to the ionic natur e of the fluid within 
the chamber and partly due to the surface area for di'ug delivery. However, 
variations in calculated circuit resistance between subjects, using the same 
chamber size, velricle and current protocol, suggests that there must also be 
variations in resistance pathways tluough the skin. Exactly tlii’ough which 
pathways current flows is unlaiown at present, but could include hair follicles and 
sweat gland ducts and thus variations in densities of these could account for some 
variation in calculated resistance between subjects.
In conclusion, we have shown that resistance is an important but previously 
unrecognised variable influencing development of hyperaemic responses during 
iontophoresis. The use of vehicles with low ionic content results in high circuit 
resistance, leading to development of high voltages that in turn are likely to 
generate electrically-induced hyperaemia. This complicates the intei'pretation of 
SNP responses. We anticipate that use of appropriate vehicles, chambers and 
iontophoresis protocols will lead to significant improvement in this technique and 
pemiit its development, thereby increasing its robust qualities as a non-invasive 
tool for endothelial assessment in clinical studies.
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C h a p ter  F o u r
Maternal obesity is associated with dysregulation of 
metabolic, vascular 
and inflammatory pathways
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Introduction
Obesity is a health problem of epidemic proportions in Western society with 10% 
of children and 20% of adults in the UK now classified as clinically obese 
(BMI>30). In the USA, these figines are even more alarming World 
wide it is estimated that more than 300 million people are clinically obese. It is 
now well established that obesity and body fat distribution strongly correlate with 
deranged metabolic function and are associated with an elevated incidence of 
cardiovascular disease (CVD)
Obesity in pregnancy has implications for morbidity and mortality in both mother 
and baby. The risk of maternal hypertensive complications such as pregnancy- 
induced hypertension or pre-eclampsia are significantly greater if the mother is 
overweight as assessed by body mass index (BMI) in early pregnancy, or 
centrally obese as assessed by waist circumference Maternal obesity also 
increases the risk of metabolic complications such as gestational diabetes. 
Furthermore, some data suggest that adiposity in the mother may critically 
influence the programming of metabolic pathways of her fetus and its risk for 
diabetes and cardiovascular disease in later life
Although there is abundant evidence concerning the effects of obesity on 
metabolic pathways and vascular function in the non-pregnant individual, such 
information is currently sparse with respect to pregnancy. Therefore, the aim of 
this study was to examine classical (lipids, blood pressure) and novel
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(inflammation, insulin resistance) cardiovascular risk factors in lean and obese 
women in the third trimester of pregnancy. To relate these lisk factors to blood 
vessel function we took advantage of recent developments in non-invasive 
microvascular assessment to examine endothelial function, using a novel 
technique ideally suited to the study o f pregnant women Our hypothesis was
that all of the pathological associations of obesity in non-pregnant subjects would 
be sustained in pregnant women in the third trimester, and as such may underlie 
the elevated risk for pregnancy complications in obese women.
Subjects and methods
Forty-seven consecutive subjects in the third trimester of pregnancy were 
recruited from antenatal clinics. These women were divided into two groups of 
lean and obese around the median early pregnancy (1 0 -1 2  weeks’ gestation) 
body mass index of 27.7 kg/m^. This median value is similar to criteria used in 
previous studies Our power calculations suggested that 20 women in each 
group would provide 90% power to detect differences in endothelial function. 
Women participating in the study were healthy and iioimotensive with no 
significant past medical history, such as peripheral vascular abnormalities, 
dermatological diseases or systemic disease processes such as diabetes mellitus 
and no relevant complications of pregnancy. In addition, no participant had 
ongoing infection or a recent history of infection or injury. The study was 
performed according to the Declaration of Helsinld and approval was granted by 
the institutional ethics committee. All women gave written informed consent.
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Clinical and Laboratory measurements
Women attended for participation in the study after an overnight fast (>10 hours) 
and underwent testing between 0900 and 1100 hours. Blood pressure was 
recorded using a standard sphygmomanometer and appropriately sized cuff (Table 
1). Fasting blood was withdrawn for lipid profile (via modification of the standard 
Lipid Research Clinics Protocol. The intra-assay and inter-assay coefficients of 
variation (CVs) for all lipid measures were less than 3%). Other measures 
included glycosylated haemoglobin (HbAlc) (High performance liquid 
clu'omatography, HA8121 analyser, Menarini Diagnostics, Berkshire, UK), 
insulin (a competitive radioimmunoassay, Coat-A-Count® I, DPC, Los Angeles, 
USA), interleuldn-6 (IL-6) (Quantikine High Sensitivity Human 11-6 
Inumuioassay, R&D systems Inc., Oxon, UK), and C-reactive protein (GRP) 
(Double antibody sandwich ELISA with rabbit anti-human CRP and peroxidase 
conjugated rabbit anti-human CRP; DAKO A/S, DK-2600 Glostiup, Denmark). 
For the CRP assay, standard cuiwes were linear up to 5mg/l and logarithmic 
thereafter. The inter-assay and intra-assay coefficients of variation were less than 
10% across the range of measured results. Plasma leptin was measured by an ‘in 
house' radioimmunoassay validated thoroughly against the commercially 
available Linco assay The intra- and inter - assay coefficients of variation 
were <7% and <10%, respectively, over the sample concentration range. The 
detection limit of the assay was 0.5ng/ml.
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Perfusion measurements
Perfusion measurements were also perfonned after an overnight fast, therefore 
ensuring no caffeine containing drinks had been consumed prior to testing. Also 
no “over the counter” medications were taken by any of the participants for at 
least 48hours prior to testing. Before testing, a ten-minute rest period was spent 
acclimatising in a temperatur e-controlled room. The women lay in a semi- 
recumbent position with the flexor aspect of the forearm exposed on an armi'est. 
Non-invasive measurement of sldn perfusion was performed by means of a laser 
Doppler imager (LDI) (Moor Instruments Ltd, UK) as described in chapter two 
and three lontophoretic application of 2.5 ml of 1% acetylcholine (ACH) and 
2.5ml of 1% sodium nitroprusside (SNP) (both Sigma, Poole UK) was performed 
using an incremental current protocol also as previously described. ACH and SNP 
are proposed to examine endothelium-dependent and independent vasodilatation. 
The vehicle for these drugs was 0.5% NaCl in deionised water. Responses were 
also observed with the vehicle alone as a control experiment. Twenty repetitive 
scans were taken with assessment of the overall response defined as the area 
under the perfusion.time cuiwe (AUG). Units of perfusion were derived from 
multiplying the perfusion.time integral by the resitance.time intégral as calculated 
by continous voltage monitorring as described on page 63.
Statistical analyses
Dose response curves were expressed as means ± SEM and compared using 2- 
way ANOVA. Metabolic parameters were compared using the Mann Whitney U
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test. Univariate analysis relationships were expressed as Pearson's correlation co­
efficients after log transformation of skewed variables. Linear regression was 
employed to examine independent associates of endothelial and metabolic 
measures.
Results
Demographic characteristics of each subject group are given in Table 1. The 
groups were not significantly different with regard to age, smoking history, parity 
and weeks of gestation. The lean gimip consisted of 24 women with median BMI 
o f 22.15kg/nf (IQ range 20-24), and the obese group 23 women with a median 
BMI of 31kg/m^ (IQ range 29-34). Although within normal ranges, diastolic 
blood pressure recorded in the first trimester and systolic blood pressure recorded 
in the third trimester, were significantly higher in obese compared with lean 
subjects. Tlri'ce women in the lean group subsequently gave birth to babies with 
birthweights below the 5^ '’ centile and one women from each group went on to 
develop mild PET at term. There were no significant differences between 
gestation of delivery or mode of delivery between the groups although the 
birthcentile of offspring was significantly greater from the obese women. All 
babies were liveborn (Table 1).
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Lean
n -2 4
Obese
11=23
P  value
1 trimester BMI (kg/m^) 22.1 (20-24) 31 (29.1-34) <0.0001
Age (years) 27 (21.5-32) 30 (25-34) 0.24
Smokers 4 7 0.26+
Parity (primigravidae) 17 15 0.68+
Gestation (weeks) 36 (35-37) 35 (34-38) 0.79
C  trim. Systolic (mmHg) 117(110-125.7) 119(110-130) 0.5
trim. Diastolic (mmHg) 65 (60-72.75) 75 (64-78) 0.035
3'^ '^ trim. Systolic (mmHg) 115(110-120) 130(120-130) 0.01
trim. Diastolic (mmHg) 70 (62-80) 80 (70-80) 0.2
Gestation o f delivery (wks) 40 (39-40) 39 (38-40) 0.44
Birth centile 40 (10 -60 ) 60 (40-90) 0.03
Vaginal delivery 68% 91% 0.07
T able 1 Demographic characteristics o f  study subjects.
All values are medians (interquartile ranges). Statistical analysis performed using Mann-Whitney 
U  test, ''' Chi-squared test. BMI -  Body Mass Index. Trim = trimester.
Plasma Analyses
Results of plasma lipid, HbAlc, IL-6, CRP, leptin and insulin concentrations are 
displayed in Table 2. Although total cholesterol and LDL-C concentrations were 
not significantly different, fasting plasma triglyceride and VLDL-C 
concentrations were significantly higher and HDL-C concentrations lower in 
obese women. Insulin and leptin concentrations were more than two-fold higher 
in obese women as compared with lean controls, although percentage of HbAlc
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demonstrated no significant difference between the two groups. IL-6 and CRP 
concentrations were also both significantly higher in the obese group (all P 
<0.05). As the women were recruited consecutively and they covered a 
continuous range of BMI, we were able to examine cross-sectional relationships 
between BMI and other parameters. Simple linear regression analysis of the 
entire cohort revealed significant coiTclation of BMI with log triglyceride (r = 
0.326, P = 0.025), log insulin (r = 0.684, P < 0.005), log leptin (r = 0.729, P < 
0.005), log IL-6 (r = 0.523, P <0.005) and log CRP (r = 0.476; P < 0.005).
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Lean Obese P  value
n=24 11=23
Lipids
Cholesterol (mmol/1) 6.35 (5.87-6.95) 6.25 (5.6-7) 0.43
LDL-C (mmol/1) 4.05 (3.75-4.79) 3.9 (3.1-4.7) 0.32
Triglyceride (mmol/1) 2 .17 (1 .9 -2 .6 ) 2.7 (2.3-3.2) 0.02
VLDL-C (mmol/1) 0.52 (0.31-0.64) 0.75 (0.6-1) 0.008
HDL-C (mmol/1) 1 .77(1 .46-1 .99) 1.55 (1.15-1.7) 0.02
M etabolic
Insulin (mu/1) 6.15 (4.47-9.5) 14.2 (11.3-27) <0.0001
H b A lc  (%) 4.4 (4.2-4.7) 4.5 (4.3-4.7) 0.89
Leptin (ng/ml) 23.4 (12.4-30.9) 56.8 (46.2-65.2) <0.0001
Inflam m atory
CRP (mg/ml) 2.13 (0.89-3.29) 4.45 (3.09-6.78) 0.0002
lL-6 (pcg/ml) 2.1 (1.7-2.8) 3.15 (2.36-3.59) 0.0016
T able 2 Lipid, other metabolic and inflammatory parameters in lean and obese groups 
All values are medians (interquartile ranges). Statistical analysis perfonned using Mann-Whitney 
U test. VLDL-C = Very Low Density Lipoprotein Cholesterol. LDL-C = Low Density Lipoprotein 
Cholesterol. HDL-C = High Density Lipoprotein Cholesterol. H bA lc = Glycosylated  
Haemoglobin. IL= interleukin, CRP = C-reactive protein.
Endothelial dependent vasodilatation
Dose dependent perfusion response to ACH was significantly greater in the lean 
as compared with obese women (Figure 1, P =0.0003). Corrected area under the 
perfusion.time cuiwe for ACH response was also calculated for each individual 
woman, and used in simple linear regression in order to consider the relationship 
of endothelial function to metabolic parameters. Log CRP and log fasting insulin 
concentrations inversely correlated with microvascular endothelial function (ACPI
1 0 2
response), (r = - 0.289, P  = 0.049, r = -0.339, P  =0.02). In addition, CRP 
coiTelated strongly with fasting insulin (r = 0.473, P =0.001).
Corrected ACH: LEAN VERSUS OBESE
1 80 0  
1 5 0 0  
^  1200
9 0 0
6 0 0
3 0 0
'lean
•obese
•obese vehicle anode 
•lean vehicle anode
2  4  6
CUMULATIVE CHARGE (mCOUL)
Figure 1: Endothelial dependent vasodilatation
Dose dependent perfusion response to Acetylcholine (ACH) in pregnant lean (n=24) versus obese 
women (n=23). Data are mean +/- standard error (SEM). P = 0.0003, ANOVA.
Endothelial independent vasodilatation
There was a small but significant difference in dose dependent perfusion 
responses to SNP between lean and obese groups (Figure 2, P =0.02).
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Corrected SNP: LEAN VERSUS OBESE
1 8 0 0
1 5 0 0
E 1200
2 4  6
CUMULATIVE CHARGE (mCOUL)
S3  9 0 0
CL
X3LL 6 0 0
3 0 0
0
•lean
•obese
•obese vehicle cathode  
•lean vehicle cathode
Figure 2: Endothelial independent vasodilatation
Dose dependent perfusion response to sodium nitroprusside (SNP) in pregnant lean (n=24) versus 
obese women (n=23). Data are mean +/- standard error (SEM). P = 0.02, ANOVA.
Predictors o f  CRP and fasting insulin
Given the recent evidence for the association of CRP with obesity and its 
independent prediction of diabetes in the non-pregnant individual we were
interested in the correlates of CRP and insulin in pregnancy. Potential correlates 
examined were based on biological plausibility and previous literature as above 
and included BMI, leptin, insulin, and IL-6. Log leptin was the strongest linear 
con elate to both CRP (r = 0.532, P < 0.001, Figure 3) and fasting insulin (r = 
0.738, P < 0.001, Figure 4) but other parameters were also correlated (data not 
shown). We therefore examined the independent predictors of CRP and insulin 
using step-wise regression analysis. For CRP, leptin (T=3.06, P -0.004) and IL-6
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(T=2.16, P  =0.036) were retained in the final model and together explained 32.2
% of its variability. For insulin, the independent predictors were again leptin
(T=3.62, P  =0.001) and BMI (T=2.21, ?  =0.032) and together accounted for
57.1% of its variability.
L ept in  v e r s u s  C R P
♦  ♦
O)
♦♦
0:5
- 0.5
Log Leptin
Figure 3: Positive correlation between log'” leptin and log'^ C-reactive protein (CRP)
concentrations (n-47) r=0.532, p<0.001.
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F igure 4: Positive correlation between log,o Leptin and logio fasting Insulin concentrations (n=47) 
r=0.738, p<0.001.
Discussion
We demonstrate for the first time, that microvascular endothelial function 
assessed by a novel non-invasive technique is impaired in obese pregnant women  
as compared with lean counterparts. These obese women also show a perturbed 
metabolic state with dyslipidaemia, as characterised by higher triglyceride and 
lower HDL-cholesterol concentration, hyperinsulinaemia, elevated leptin 
concentrations and a low-grade inflammatory response. Interestingly, just as in 
the pre-diabetic state, this perturbation occuiTed in advance o f  any notable glucose 
dysregulation, since H B A lc  concentrations were near identical. Thus, just as in 
the non-pregnant state, obesity in pregnancy results in a plethora o f  metabolic and 
vascular abnonnalities that could collectively exacerbate the risk o f  maternal
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complications. As the pattern of metabolic and inflammatory perturbances 
associated with obesity is also observed in our group of pregnant women, this 
indicates that the marked pregnancy-associated hormonal increments (e.g. 
oestrogen, progestogen, and hormone placental lactogen) do not over-ride these 
changes.
Microvascular function was investigated using a well-tolerated in-vivo method of 
assessment, ideal for the pregnant patient. LDI in combination with iontophoresis 
examines the cutaneous microcirculation, a robust surrogate marker of vascular 
function in other vascular beds. Reduced responsiveness to iontophoretic 
administration of ACH has been observed in diabetes and
hypercholesterolaemia and in both these conditions there is a parallel reduction 
of the ACH response in the forearm circulation (a predominantly skeletal muscle 
vascular bed) assessed by venous occlusion plethysmography Furthermore,
assessment of endothelial vasomotion in peripheral arteries has been shown to 
correlate with and relate directly to coronary dysfunction
We noted not only a reduced response to ACH (endothelial dependent), but also 
reduced responses to administi’ation of SNP (endothelial independent). Therefore 
impaired perfusion responses in obese subjects may not necessarily represent 
solely endothelial dysfunction, but vascular dysfunction further downsti’eam at the 
level of the vascular smooth muscle. However, the smaller magnitude of the SNP 
response as compared with the ACH response may suggest endothelial 
dysfunction to be relatively more important. Other groups utilising laser Doppler
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imaging teclmology to investigate microvascular fmiction in diabetic subjects and 
healthy relatives of Type II diabetics, a condition strongly linked with obesity, 
also demonstrated impaired endothelial independent vascular responses.
These observations may have particular significance with regards to maternal 
vascular complications. Maternal obesity is established as a significant risk factor 
in the development of hypertensive complications of pregnancy, particularly pre­
eclampsia. Deranged endothelial function is proposed as the 
pathophysiological mechanism of this condition and several ex-vivo techniques 
have supplied evidence of altered vascular reactivity in pre-eclampsia.
Thus the metabolic, inflammatory and functional abnormalities which we have 
described for the first time in obese pregnancy, may predispose to vascular 
compromise and may contribute to the mechanism by which maternal adiposity is 
associated with an elevated risk of pre-eclampsia.
This report, to the best of our Imowledge, is also the first to comprehensively 
demonstrate that obesity in pregnancy is associated with hypertriglyceridaemia, 
and low HDL. Tliis dyslipidaemic pattern is consistent with the metabolic 
syndrome Interestingly, although LDL-cholesteroI was not raised, smaller,
dense, atherogenic LDL species are likely to be elevated, since circulating 
triglyceride-rich particles drive production o f smaller particles from larger more 
buoyant species Evidence fiom the cardiovascular arena links such a pattern, 
directly and indirectly, to endothelial dysfunction and greater oxidative stress 
Indeed, we and others have shown the same pattern in pre-eclampsia
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Clearly, prospective studies are required to examine whether the magnitude of the 
lipid dysregulation in the third trimester, associated with maternal obesity, is more 
or less exaggerated than would be seen in the non-pregnant state.
Our novel findings of elevated concentr ations of IL-6 and CRP in obese pregnant 
women agiee with the recent literature implicating adiposity as a key factor in 
low-grade clnonic inflammation We found that IL-6 was 50% higher and
CRP was almost double in the obese pregnant women relative to the lean group. 
High CRP correlates with endothelial dysfunction and impaired insulin 
sensitivity in non-pregnant populations and predicts risk for type 2 diabetes 
in women In line with these observations, we noted that CRP correlated 
negatively with acetylcholine-mediated endothelial vasodilatation (P =0.049) and 
positively with fasting insulin (P =0.001). Thus obesity driven inflanunation in 
pregnancy could be implicated in pathogenesis of pre-eclampsia and gestational 
diabetes. Indeed, some suggest that pre-eclampsia is a disease of inflammation 
with endothelial cells in maternal systemic vessels becoming activated and 
damaged by circulating factors.
As expected concentrations of leptin, an adipocyte derived m o l e c u l e w e r e  
more than two-fold higher in the obese women. Leptin is also produced by the 
placenta so it is not entirely clear from our data to what extent the high leptin 
reflects adipose tissue-derived or placental leptin. However, as leptin 
independently correlated with both C-reactive protein and fasting insulin levels in 
our cohort, we suggest a dominant role for adiposity in the elevated leptin levels
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in obese women. In line with this, we have suggested previously that elevated 
leptin concentrations in pregnancy could be linlced to changes in maternal fat 
mobilisation These combined obseiwations further emphasise the importance 
of adipose tissue as an active metabolic organ even in pregnancy
Finally, could the above metabolic and vascular disruption have adverse 
consequences for fetal programming? Firstly, altered maternal vascular function 
and dyslipidaemia may dysregulate blood and nutrient flow to the developing 
fetus. Secondly, a higher inflammatory burden may be damaging since a recent 
animal study demonstrated that offspring of rats injected with IL-6 tlnoughout 
pregnancy had greater body fat and in male offspring reduced insulin sensitivity.
A pro-inflammatory phenotype is also linked to miscarriage Finally, data 
exists linldng maternal obesity to cardiovascular and metabolic disease in her 
offspring. A population-based study from Finland demonstrated a positive 
relationship in short mothers between maternal body mass index on admission to 
laboin ward and friture death rate from coronary heart disease in male offspring. 
Higher adult rates of type 2 diabetes have also been reported in offspring of 
mothers who were above average weight in pregnancy in a different population 
Clearly, the dysregulation in several risk factor pathways described herein 
may be relevant to this process and importantly such effects need not include 
glucose dysregulation. However, this suggestion remains speculative and more 
data linldng maternal obesity with the health of offspring are needed.
We recognise that our study has limitations in that it is cross-sectional in nature
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and therefore further prospective data are now required. However, strengths 
include a comprehensive assessment of a panel of classical and novel risk factors 
and robust methodology.
In conclusion, these comprehensive data demonstrate for the first time that, as in 
non-pregnant obese individuals, obesity in pregnancy is associated not only with 
marked hyperinsulinaemia (in advance of glucose dysregulation) and deranged 
lipids, but also impaired endothelial function and inflammatory up-regulation. 
Such perturbation may contribute to the risk for maternal complications in obese 
women and as a result may also be relevant to fetal programming of adult 
vascular disease. Clearly, these data provide fmther rationale to examine the 
potential benefits of pre-conceptual weight loss and antenatal exercise.
I l l
C h a p ter  F ive
Enhancement of endothelial function by pregnancy: 
inadequate response in women with type I diabetes.
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Introduction
Type 1 diabetes is an established risk factor for the development of macro- and 
micro-vascular disease complications that predispose to much of the increased 
morbidity and mortality associated with diabetes, hidividuals with type I diabetes 
mellitus are recognised to be at extremely high risk for the development of 
cardiovascular disease and have a tlnee to six fold increased risk of early 
cardiovascular death before the age of 60, as compared with non-diabetics.
Normal pregnancy is characterised by a progressive increase in insulin resistance 
and to meet the increasing demands of the feto-placental unit, glucose 
production also increases in late pregnancy. These physiological adaptations of 
pregnancy may accelerate the development of microvascular complications in 
pregnant women with diabetes, potentially increasing the risk of maternal 
vascular disease such as pre-eclampsia a condition also associated with
insulin resistance. The fetus is also adversely affected in diabetic pregnancy. 
Maternal hyperglycaemia in early pregnancy is associated with an increased 
incidence of fetal anomalies and poor glycaemic control tlnoughout pregnancy 
results in fetal hyperinsulinaemia and secondary macrosomia.
A considerable body of evidence exists concerning potential mechanisms 
associated with the increased morbidity and mortality associated with diabetes. 
One potential unifying hypothesis is that of altered micro-vascular reactivity. This 
phenomenon has been described in pregnant women with gestational diabetes 
using wire myography however to om* Imowledge such experiments have not
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been performed in-vivo in diabetic women either antenatally or postpartum. 
Therefore, the aim of this investigation was to examine microvascular function 
using a well-tolerated in-vivo teclmique, in the antenatal and postpartum periods 
in women with type I diabetes and healthy controls. We also examined whether 
conventional (lipids) or novel vascular risk factors (inflammatory parameters) 
were perturbed in such patients. Our hypothesis was that microvascular function 
would be impaired in non-pregnant diabetic women as compared with healthy 
controls, and that tins impairment would be evident even during pregnancy 
perhaps in association with deranged risk factors.
Subjects and Methods.
The study was divided into two portions comparing diabetic women and healthy 
controls in the antenatal and postnatal periods. All work was performed according 
to the Declaration of Helsinld, approval was granted by the institutional ethics 
committee and all patients gave written informed consent.
I. 15 women with type I diabetes (no microscopic proteinuria, retinopathy or 
ketonuria) and 30 pregnant controls, were recmited from antenatal clinics in 
the 3rd trimester of pregnancy. Women participating in the study were 
healthy and normotensive with no significant past medical history, such as 
peripheral vascular abnormalities or dermatological diseases and no relevant 
complications of pregnancy.
II. The above groups were invited to return at least 4 months after delivery. Of 
the original group, 9 of the diabetic and 16 of the control participants
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attended for postpartum assessment. Exactly the same protocol was followed 
at the postpartum and antenatal assessments.
Clinical, laboratory and perfusion measurements
Controls attended for participation in the study after an overnight fast and 
imderwent testing between 9 and 11 am. Women with type I diabetes were seen 
pre-midday meal due to difficulty enforcing an overnight fast in out-patients in 
whom glycaemic control is tight. Nevertheless, all diabetic women were 
instructed to have a light brealcfast prior to 7am in the morning and examination 
was performed after 1200. Blood pressure was recorded using a standard 
sphygmomanometer and appropriately sized cuff and a blood sample was 
withdi'awn for lipid profile, glycosylated haemoglobin (HbAlc), and C-reactive 
protein (CRP) as descibed in previous chapter. In addition, assessment of soluble 
vascular cell adhesion molecule (VCAM) (Parameter Human sVCAM-1 
Immunoassay, R&D systems Inc., Oxon UK) was performed. In the diabetic 
women, random capillary glucose was recorded before testing. (One II One 
glucometer and reagent strips, Lifescan, Buckinghamshire, UK). Perfusion 
measurements were performed as previously described in methods chapters and 
chapter four. Units of perfusion were derived from multiplying the perfusion.time 
integral by the resitance.time integral as calculated by continous voltage 
monitorring as described on page 63.
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Statistical analyses
Dose response cui-ves were expressed as means ± SEM and comparisons were by 
2-way ANOVA. Other data are expressed as medians with the interquartile range 
as the measure of variability. For these data the Mann Wliitney U test for 
comparisons between groups and Wilcoxon test for comparison within groups 
were used as appropriate. Linear relationships between variables were examined 
using the Pearson correlation coefficient after normalising skewed variables by 
log transformation. Regi'ession analysis was used to test for independent 
associations between variables.
Results
la. Antenatal diabetic versus control
Demographic characteristics are given in Table 1. Although all women were 
tested in the third trimester, gestation differed by three weeks in the two groups. 
Despite excellent glycaemic control the birth centile was significantly gieater in 
the diabetic births (85 (64-98) vs 50 (25-75); p=0.0067).
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Antenatal diabetic 
(n=15)
Antenatal 
Control (n=30)
P
value
A ge (years) 29 (25-31) 29 (25-32) 0.99
Gestation (weeks) 32 (29-35) 35 (34-37) 0.001
BMI (k g /n f ) 26.5 (23.4-28) 26.7 (21.8-30.2) 0.8
Systolic (mmHg) 120(110-130) 120(110-130) 0.4
Diastolic (mmHg) 75 (67-80) 75 (69.5-80) 0.8
First trim Systolic (mmHg) 114(100-120) 119(112-126) 0.13
First trim diastolic (mmHg) 67 (60-72) 71 (62-77) 0.25
Primigravid 9 21 0.8+
Smokers 2 5 0.959+
Table 1 Demographic characteristics o f  study subjects.
A ll values are medians, (interquartile ranges). Statistical analysis performed using Mann-Whitney 
U test, Chi sqared test. BMI = Body Mass Index. A ll diabetic women were treated with insulin 
and had no microalbuminuria.
Endothelial dependent vasodilatation
There was a significant difference in dose dependent perfusion responses to ACH 
(Figure la ) between diabetic and control groups (p<0.001). Median response to 
ACH (as defined by corrected area under the perfusion.time cuiwe (AUC)) was 
significantly lower in the diabetic group (8176 [3618-11434] vs 13235 
PUMQ.min [9083-16809], p=0.0017). Tins difference remained after adjusting 
for differences in gestation between the two groups (T=-2.39, p=0.022).
117
P<0.001
.5  1200
S  1000
Û. 800
2 4 6
Cumulative charge (mCoulombs)
Figure la : Endothelial dependent (ACH) vasodilatation (pregnancy).
Dose dependent perfusion response to ACH in pregnant controls (n=30, ♦) versus diabetics (n=l 5, 
•  ). Data are mean +/- standard error (SEM). P < 0.001, 2-way ANOVA.
Endothelial independent vasodilatation
Dose dependent perfusion responses to SNP were also lower in the pregnant 
diabetic women as compared with healthy pregnant controls. (Figure lb , 
p=0<0.001) Median vascular response to SNP (AUC) was also significantly less 
in the diabetic (6339 [2712-7568] vs 9130 PUMQ.min [7462-11489], p=0.0007). 
This difference remained after adjusting for gestation. (T=-2.83, p=0.007).
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Figure lb ; Endothelial independent (SNP) vasodilatation (pregnancy).
D ose dependent perfusion response to SNP in pregnant controls (n=30, ♦) versus diabetics (n=15, 
• ) .  Data are mean +/- standard error (SEM). P < 0.001, 2-way ANOVA.
Plasma Analyses
Results of plasma measurements are displayed in Table 2. The concentration of 
HbAlc was greater in the women with diabetes than controls. The median 
capillary blood glucose in women with diabetes at the time of testing was 
6.15mmol/1 (IQ range 5.38-9.73). There was no correlation between AUC for 
ACH response in relation to capillary blood glucose (r=-0.069, p=0.815), although 
a non-significant inverse relationship was observed between HbAlc and ACH 
response (r=-0.384, p=0.16). Adjustment for HbAlc resulted in a loss of 
significance in ACH response between cases and controls. (T=-0.64, p=0.523). 
There were no differences in plasma lipoproteins in the antenatal period between
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the groups. Soluble VCAM-1 concentration was similar in both groups. 
Compared with controls, CRP concentrations were significantly higher in diabetic 
women in the antenatal period, although this observation did not persist after 
adjustment for gestation (T=1.43, p-0.162). CRP did coirelate with AUC for 
ACH response in the control group ( i -  -0.37, p=0.043) but not in the women with 
diabetes (r=G.G41, p=G.885). Adjustment for CRP did not attenuate the case- 
control difference in ACH response. (T=-2.98, p=G.G05).
Antenatal diabetic 
(n=15)
Antenatal control 
(n=30)
P
value
P
value*
Cholesterol (mmol/1) 6.05 (5-6.95) 6.47 (5.7-7.2) 0.25 0.44
Triglyceride (mmol/1) 2.45 (2-2.95) 2.37 (2.05-3) 0.66 0.59
VLDL-C (mmol/1) 0.55 (0.25-0.8) 0.6 (0.34-0.8) 0.64 0.84
LDL-C (mmol/l) 3.75 (2.5-4.4) 4.05 (3.5-5.07) 0.15 0.24
HDL-C (mmol/l) 1.8(1.65-2.0) 1.55(1.4-1.8) 0.06 0.32
H bA lc (%) 5.8 (5.5-6.1) 4.55 (4.3-4.7) <0.001 <0.001
CRP (mg/ml) 3.81 (2.47-8.15) 2.74(1.53-4.4) 0.03 0.162
VCAM (ng/ml) 323 (254-370) 330 (249-390) 0.82 0.37
Table 2 Results of lipid profiles, HbAlc, C-reactive protein (CRP) and soluble 
VC AM. Pregnant diabetic women versus controls. All values are medians, 
(interquartile ranges). Statistical analysis perfonned using Mann-Wliitney U test. 
VLDL-C = Very Low Density Lipoprotein Cholesterol. LDL-C = Low Density 
Lipoprotein Cholesterol. HDL-C = High Density Lipoprotein Cholesterol. HbAlc  ^
Glycosylated Haemoglobin. CRP = C-reactive protein. VCAM = vascular cellular 
adhesion molecule. P value'*' = after adjustment for gestation.
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Ib. Postnatal results: diabetic versus control.
Postnatal comparison of control and diabetic women showed no significant 
difference in BMI (22.7 versus 25.6kg/nf, p = 0.28), blood pressure (Systolic:
115 versus 112mmHg, p=0.6; diastolic: 76 versus 76mmHg, p=0.98) or weeks 
elapsed since delivery (31.5 versus 28, p-0.23). The proportion of subjects breast­
feeding (3 (18.8%) versus 3 (30%), chi squared p=0.412) or taking oral 
contraceptives (4 (25%) and 2 (22.2%), chi squared p=0.88) were also not 
significantly different.
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Endothelial dependent and independent vasodilatation
Dose dependent perfusion responses to ACH and SNP were significant less in the 
women with diabetes than the control group, both p<0.001 (F igures 2a and 2b).
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Figure 2a: Endothelial dependent (ACH) vasodilatation (control and diabetic); Antenatal versus 
postnatal. Dose dependent perfusion response to ACH in control women: antenatal (n=16; ♦) 
versus postnatal (n=16; dashed line ♦ ) and diabetic women: antenatal (n=9; •) versus postnatal 
(n=9, dashed line •). Data are mean +/- standard error (SEM). .'. = control antenatal versus 
postnatal: P = 0.018; ({) = diabetic antenatal versus postnatal: P = 0.029, 2-way ANOVA.
II. Antenatal versus postnatal in diabetic and control groups.
Endothelial dependent vasodilatation
There was a significantly greater response to ACH in pregnancy compared with 
the postpartum period as represented by dose dependent perfusion responses in 
both control (p=O.OI8) and diabetic (p=0.029) groups (Figure 2a).
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Endothelial independent vasodilatation
In healthy controls a greater dose dependent perfusion response to SNP was 
observed in pregnancy as compared with the postpartum period (p=0.01). In the 
diabetic women this effect was also observed but was smaller in magnitude and 
did not attain significance (p = 0 .105) (Figure 2b).
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Figure 2b: Endothelial independent (SNP) vasodilatation (control and diabetic): Antenatal versus 
postnatal. Dose dependent perfusion response to SNP in control women: antenatal (n=16;#) 
versus postnatal (n=16; dashed line ♦ ) and diabetic women: antenatal (n=9; •) versus postnatal 
(n=9, dashed line •). Data are mean +/- standard error (SEM). # = control antenatal versus 
postnatal: P = 0.01; x = diabetic antenatal versus postnatal: P = 0.105, 2-way ANOVA.
123
Plasma Analyses (Table 3)
In both groups, lipid and lipoprotein concentrations were significantly elevated in 
pregnancy in comparison with the postpartum period. CRP concentrations 
demonstrated a trend to be elevated during pregnancy in patients with diabetes 
(p<0.10). HbAlc results were similar in the control group during and after 
pregnancy but a marked increase was noted in women with diabetes post 
pregnancy. Postpartum VCAM-1 concentrations tended to increase in the women 
with diabetes and fell in the control subjects. However, VCAM-1 levels were 
higher in the diabetic women than controls in the postpartiun period (p<0.005).
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Controls Type 1 diabetes
Antenatal Postnatal P Antenatal Postnatal P value P
(n=16) (n=16) value (n=9) (11=9) ConlTol 
V diabetic 
at post 
natal visit
Lipop roteins
Cholesterol 6.6 4.8 <0.001 6.05 4.4 0.009 0.46
(mmol/l)
Triglyceride
(5.S-7.5)
2.22
(3.8-5)
0.85 <0.001
(5.2-6.5)
2.3
(3.9-5.0)
0.85 0.013 0.75
(mmol/l)
VLDL-C
(1.9-3)
0.6
(0.7-1.1) 
0.22 0.001
(1.9-3.3) 
0.55
(0.7-1.6) 
0.25 0.08 0.55
(mmol/l)
LDL-C
(0.3-0.9)
4.32
(0.1-0.4) 
2.95 0.001
(G.3-0.7)
3.75
(0.1-0.5) 
2.5 0.009 0.25
(mmol/l)
HDL-C
(3.5-S.2)
1.52 1.32 0.01
(2.7-4.1)
1.8
(2.1-2.8)
1.45 0.009 0.73
(mmol/l) (1.2-1.9) (1.1-1.7) (1.7-2.0) (1.2-1.7)
Inflam m ation
CRP 2.13 1.15 0.48 3.44 2.95 0.076 0.174
(mg/ml)
VCAM-1
(0.9-3.9) 
369
(0.3-3.3)
344 0.103
(2.3-7.6)
351
(0.9-6.7)
419 0.124 0.004
(ng/ml) (321-424) (285-393) (299-391) (385-476)
Glucose control
H bA lc 4.6 4.7 1.00 5.8 7.6 0.033 <0.001
(%) (4.4-4.8) (4.4-4.9) (5.3-5.9) (5.9-7.7)
Table 3 Results of lipid profiles, HbAlc, soluble VCAM and CRP. Antenatal versus 
postnatal (control and diabetic).All values are medians (interquartile ranges). Statistical 
analysis performed using Mann-Wliitney U test. VLDL-C = Very Low Density 
Lipoprotein Cholesterol. LDL-C = Low Density Lipoprotein Cholesterol. HDL-C = High 
Density Lipoprotein Cholesterol. HbAlc = Glycosylated Haemoglobin. VCAM = 
vascular cellular adhesion molecule. CRP = C-reactive protein
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Enhancement o f  endothelial function by pregnancy.
In the control group, women with lowest responses to ACH postpartum showed 
the greatest improvement during pregnancy, whereas those with the highest 
vasodilator responses postpartum showed the least change with pregnancy. This 
was demonstrated by correlating the change in response to ACH (AUC) between 
postpartum and antenatal time points with the ACH response postpartum (r^= 0.84 
P <0.001). (Figure 3a).
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Figure 3a: Relationship of change in endothelial function (ACH response) in 
pregnancy to postnatal response (control). Inverse correlation between the 
percentage change in non-pregnant to pregnant log transformed endothelial 
dependent (ACH) perfusion and postpartum log transformed endothelial 
dependent (ACH) perfusion response in the control gioup. (n = 16) r^  = 0.82, 
p=3.83xlO \
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This relationship was also near significant in women with diabetes (r = 0.40, P = 
0.065) showing a similar gradient of association (Figure 3b).
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Figure 3b: Relationship of change in endothelial function in pregnancy to 
postnatal response (diabetic). Inverse correlation between the percentage change 
in non-pregnant to pregnant log transformed endothelial dependent (ACH) 
perfusion and postpartum log transformed endothelial dependent (ACH) perfusion 
response in the diabetic group, (n = 9) r^  = 0.4, p=0.07.
Discussion
To the best of our knowledge, we have demonstrated for the first time using an in- 
vivo technique, the presence of microvascular dysfunction in the forearm skin 
resistance vessels of pregnant women with type I diabetes and no clinical 
evidence of microvascular complications. We demonstrate reduced vasodilator
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responses to both endothelial dependent and independent stimuli, in contrast to 
previously reported work in diabetic pregnancy. This finding was observed 
using a well tolerated non-invasive method of assessment, ideal for the pregnant 
patient. We have also been able to provide data concerning microvascular 
function in the non-pregnant state. In both groups the magnitude of improvement 
in ACH response with pregnancy correlated inversely with responses postpartum. 
In other words, our results indicate that pregnancy optimises vascular function in 
both healthy women and in those with diabetes. However, in the women with 
diabetes this improvement in vascular function is insufficient even to attain 
responses seen in healthy non-pregnant women. This finding suggests either a 
persistent vascular defect in young women with type I diabetes or the presence of 
toxic circulating factors. Oui' data, which considered circulating lipids, CRP and 
HBAlc, suggest that even a modest level of clnonic hyperglycaemia is 
detrimental to vascular function.
Unlike previous hypotheses concerning the relationship of advancing gestation 
and endothelial ftinction pregnancy may not indeterminately improve 
endothelial flmction in all women. We propose there exists a gradient of vascular 
responses by which pregnancy can enliance vascular function, conferring most 
benefit to those with the most inadequate non-pregnant endothelium-dependent 
vasodilator mechanisms (Figures 3a and 3b). It is notable that sVCAM-1 
concentration was significantly greater in the diabetic women in comparison to 
controls in the postnatal period, whereas during pregnancy the concentrations
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were similar. Thus, we suggest that circulating markers of vascular function do 
not necessarily provide a sensitive examination of vascular function.
Previous investigations of microvascular function in non-pregnant type I diabetes 
have proposed endothelial dysfunction as a mechanism contributing to an 
increased incidence of cardiovascular complications within this group.
However, we have described not only a reduced response to an endothelial 
dependent vasodilator, but also reduced responses to an endothelial independent 
vasodilator in diabetic women, thus excluding any presumption concerning the 
function or integrity of the endothelial cell. These results concur with similar 
findings in type I diabetic subjects and their healthy relatives by other gi’oups 
163 149^  There may or may not be impaired production of endothelial derived nitric 
oxide (NO), however oui’ results suggest alterations fui’ther downstream in the 
microvascular tree at the level of the vascular smooth muscle. This may indicate a 
problem with inactivation of endothelial derived NO or impaired function at the 
level of the vascular smooth muscle cell. In many studies of diabetic vascular 
function, hyperglycaemia is proposed as the main protagonist in the mediation of 
complications. Hyperglycaemia is believed to induce multiple changes in 
intracellular metabolism such as activation of the polyol pathway. Also, 
hyperglycaemia results in non-enzymatic glycation of circulating cells and 
proteins resulting in production of advanced glycation end products (AGEs).
These molecules quench NO and in combination with free radicals such as 
superoxide anions, which directly inactivate NO, are responsible for reducing the
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bio-availability of NO. In our subjects, the difference between ACH responses 
in women with diabetes and controls was eliminated after adjustment for HbAlc. 
Our obseiwation of a combined reduction in responses to endothelial dependent 
and independent vasodilatation may also reflect micro-vascular sclerosis, a more 
physical loss of vasodilator reserve. hi the early stages of diabetes some groups 
have suggested that increased microvascular flow and consequent increased 
capillary pressure results in up-regulated tissue perfusion, which may result in 
further shear stress applied to the vessel wall and consequent extra-vascular 
matrix proteins production as an injury response. The resultant effect may be 
micro-vascular sclerosis and impairment in vasodilatory reserve and 
autoregulation.
We observed that the lipoprotein pattern was not perturbed in pregnant women 
with type 1 diabetes and if anything, HDL-cholesterol concentration was higher. 
This finding broadly concuis with existing data horn non-pregnant populations in 
which the lipoprotein pattern appears anti-atherogenic in individuals with type I 
diabetes with optimal glycémie control Such a ‘nonnaT lipid pattern in 
diabetic individuals is proposed to reflect insulin upregulation of key lipid-related 
enzymes such as lipoprotein lipase, responsible for breakdown o f triglyceride-rich 
lipoproteins. Of note, a recent study of non-pregnant patients with type I diabetes 
reports elevated CRP concentrations in association with elevated VCAM-1 levels 
implicating a potential role for inflammatory mediators in the accelerated vascular 
disease of this gimip hiflammatory proteins such as CRP have also been
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independently and strongly correlated with impaired endothelial function in both 
healthy non-pregnant individuals and those with existing vascular disease In 
our cohort, CRP was correlated with ACH responses in the control subjects, and 
has been linked to endothelial function in other diseases. However, although 
higher in cases, the difference in CRP was not significant following adjustment 
for gestation and in addition, CRP did not attenuate the significant case-control 
difference in ACH responses. Clearly, larger studies are needed to addi'ess CRP 
changes in pre-gestational diabetes.
In conclusion, using an in vivo method of microvascular assessment, we have 
demonstrated that pregnancy optimises vascular function in both healthy women 
and in those with diabetes. However, in women witli diabetes this improvement is 
insufficient even to attain responses seen in healthy non-pregnant women. Our 
data suggest a key role for the cluonic effects of hyperglycaemia in the impaired 
vascular responsiveness in such women. These important observations provide an 
insight into mechanisms underlying pregnancy-associated and long-term vascular 
risk in women with type 1 diabetes.
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C h a p ter  S ix
Metabolic, inflammatory and vascular derangement in 
pre-eclampsia and intrauterine growth restriction: 
adverse effects of adiposity and leptin.
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Introduction
Pre-eclampsia is a pathological condition associated specifically with human 
pregnancy. It is characterised by a triad of symptoms, namely elevated blood 
pressure, proteinima and oedema and its associated complications contribute 
significantly to maternal mortality and morbidity At present the only 
definitive treatment is termination of pregnancy with a consequent contribution of 
40% to the iatrogenic premature delivery rate and associated perinatal morbidity 
and mortality.
Pre-eclampsia is a multisystem disorder of which the patho-physiological 
mechanisms are poorly understood. Healthy pregnancy is associated with a 
significant drop in peripheral vascular resistance reaching a nadir around 20 
weeks gestation before climbing to non-pregnant levels by the end of the 3'^ 
trumester, despite increasing cardiac output and blood volume Tlris 
physiological mechanism is believed to result from an increase in the production 
o f endothelial cell derived nitric oxide. Ex-vivo experiments have demonstrated 
augmented endothelial dependent vasodilation and increased intraluminal flow in 
response to shear stress in small resistance vessels from pregnant women. In- 
vivo assessment of endothelial dependent vasodilator mechanisms using both 
venous occlusion plethysmography and brachial artery Doppler ultrasound 
assessment of flow-mediated vasodilatation have confirmed these observations in 
pregnant subjects and suggest that endothelial dependent vasodilatation correlates
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positively with gestation. Pre-eclampsia, in terms of the maternal 
manifestation of vasomotor dysfunction/hypertension, has been proposed to result 
secondary to a lailm e in these mechanisms.
Endothelial activation and dysfunction are suggested as important mechanisms in 
the pathophysiology of pre-eclampsia. Increased sensitivity of maternal 
vasculature to angiotensin II can be demonstrated before hypertension develops 
Markers of increased coagulation activation can be demonstrated weeks to 
months before the development of the clinical disorder. Several ex-vivo
techniques have also supplied direct evidence of altered vascular reactivity in pre- 
eclampsia. Myographic teclmiques have demonstrated reduced endothelial 
dependent vasodilatation in isolated subcutaneous resistance vessels from women 
with pre-eclampsia  ^  ^\  However the mechanism by which this state arises is 
as yet elusive. One theory proposes impaired trophobiast invasion of the spiral 
arterioles to result in abnoiinal placentation and a high resistance circulation. This 
theory is also proposed in the gi'owtli restricted pregnancy despite the absence of 
maternal effect. This may result in episodes of hypoxia and ischaemia liberating 
oxidised molecules and inflanunatory cytokines, suggesting pre-eclampsia to be a 
disease of inflammation These circulating molecules may pass into the 
maternal circulation to activate and damage endothelial cells.
Pre-eclampsia is also associated with significant metabolic derangement. Fasting 
triglyceride concentrations are doubled compared with normal pregnancy and a 
tlnee-fold increase in VLDL and LDL-llI concentrations are also observed.
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Small dense LDL III molecules are Icnown to be highly atherogenic and can 
induce endothelial dysfunction and insulin resistance, also associated with pre­
eclampsia. It is of note that the specific vascular lesion of pre-eclampsia ‘acute 
atherosis with lipid laden foam cells’ as observed in spiral arterioles of the 
placental bed, is similar to that seen in atherosclerosis in the non-pregnant 
Using myogi-aphic techniques, Hayman et al related lipid concentrations, 
specifically reduced apo-AI (the major lipoprotein in HDL particles), to impaired 
endothelial function. Myométrial vessels Rom healthy pregnant women, 
incubated with plasma from pre-eclamptic women demonstrated reduced 
endothelial dependent vasodilatation providing evidence of the detrimental effect 
of a circulating factor upon endothelial flinction.
Of interest, adiposity has been proposed to be a predictor of morbidity and 
mortality in cardiovascular disease and is associated, similarly to pre-eclampsia, 
with hyperinsulinamia, hypertriglyceridaemia, reduced HDL concentrations, 
impaired endothelial function and hypertension. Obesity is also established as a 
significant risk factor in the aetiology of pre-eclampsia. Most published work 
concerning endothelial flinction in pre-eclampsia has not considered or controlled 
for the effects of body mass index (BMI).
In-vivo teclmiques for assessment of microvascular function have not, as yet, 
demonstrated impaired endothelial cell function in pre-eclampsia.
We took advantage of developments in laser Doppler imaging technology, a non-
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invasive teclinique used in combination with iontophoresis of endothelial 
dependent and independent vasodilators, to investigate cutaneous microvascular 
function in pre-eclamptic women. We also compared vascular function with 
circulating markers of endothelial damage and with simultaneously measured 
lipid and cytokine levels. We considered pre-eclamptic women in relation to their 
first trimester BMI and to BMI matched healthy pregnant controls. As pre­
eclampsia and pregnancies complicated with intra-uterine growth restriction 
(lUGR) are proposed to arise from similarly impaired placentation, we included a 
cohort of women with lUGR.
Our aims were twofold. Firstly, to examine if  microvascular endothelial function 
is altered in women with PE and in women with gi'owth restricted pregnancies 
compared to healthy controls. Secondly, to comprehensively characterise 
candidate pathways proposed to mediate systemic disease simultaneously in 
women with PE and lUGR.
Subjects and Methods.
1. 15 women with PE were consecutively recruited. PE was defined as a blood 
pressure of greater than 140/90 mmHg on two separate occasions 4 hours apart or 
a single recording of a diastolic pressui’e of 110 mmHg, both in association with 
proteinuria consistent with or greater than two pluses on dipstick testing. Of the 
15 pre-eclamptic women only 12 agi'eed to be tested with the EDI.
2. 16 women with pregnancies complicated with lUGR were also recruited. lUGR
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was defined primarily by an ultrasound diagnosis of fetal abdominal 
circumference of less than the 5*'’ centile. In addition 6 women had an amniotic 
fluid index of less than 6cm and/or abnormal end diastolic flow on umbilical 
artery Doppler waveform.
3. 30 normotensive control subjects with similar BMI to the PE group were 
recruited. A further subgroup of 16 controls with similar BMI to the women with 
lUGR was also defined.
Women participating in the study had no significant past medical history, such as 
peripheral vascular abnormalities, dermatological diseases or systemic disease 
processes such as diabetes mellitus. The study was performed according to the 
Declaration of Helsinld, approval was granted by the institutional ethics 
committee and all patients gave written informed consent. Clinical and laboratory 
measurements were performed as described in previous chapters after an 
overnight fast. In addition analysis of soluble adhesion molecules, ICAM-l and e- 
selectin were perfonned. (Parameter Human sICAM-1 and e-selectin 
Immunoassay, R&D systems Inc., OxonUK) O f the 15 pre-eclamptic women 
only 12 agreed to be tested with the laser Doppler perfusion imager. Perfusion 
measurements were perfomred as described in previous chapters using the low 
charge, incremental current delivery iontophoresis protocol. An assessment of 
the overall response to di'ugs was obtained by taking the area under the 
perfi.ision.time curve (AUC). Units of perfusion were derived from multiplying
137
the perfusion.time integral by the resitance.time integi’al as calculated by 
continous voltage monitomng as described on page 63.
Statistical analyses
Dose response curves were expressed as means ± SEM and compared using 2- 
way ANOVA. Metabolic parameters were compared using the Mami Wlritney U 
test. Univariate analysis relationships were expressed as Pearson's correlation co­
efficients. Distribution of plasma results were assessed for normality and where 
skewed, considered as their log transfomied integral.
Results
Demographic characteristics of each subject group are given in Table 1. There 
was no significant difference in BMI, age, smoking history, parity and gestation of 
examination between controls and PE women. Women with lUGR were found to 
be significantly leaner than PE women (lUGR: 22.2 (20-25.4) kg/m^ Vs PE: 
26(23.5-27.8) kg/m^, p=0.044) therefore they were matched directly for BMI with 
a subgroup of the controls. Compared to this gi'oup women with lUGR had a 
higher proportion of smokers and were examined at an earlier gestation, reflecting 
the high-risk nature and pre-term identification and delivery of these women. 
Gestation of subsequent delivery was significantly less in the PE women and 
women with lUGR as compared with controls. Median birthweight centile of 
babies born to mothers with PE was significantly less than controls (50 vs 25, 
p=^0.024), and as expected women with suspected antenatal lUGR, gave birth to
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babies with weights less than the fifth percentile for gestational age. Only 50% of 
women with PE and lUGR achieved vaginal deliveries, which was significantly 
less than that seen in controls (80%). Of interest the section rate in the lean conti ol 
group was only 9% compared with 20% in die overweight control group.
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Table 1: Demographic characteristics of study subjects.
C ontrol PE Control lU G R
(n=30) (11=15) (n= l 6) (n=16)
Booking BMI (kg/m^) 26.8 (21.8-30.2) 26.(24-27.8) 22.4 (20-24.6) 22.2 (20-25.4)
A ge (years) 29 (25-32) 27 (22-29) * 26 (21-32) 25 (20.2-30.0)
Smokers 5(16.7% ) 5 (33.3%) 1 (6.2%) 7 (44%) t
Parity (primigravidae) 21 (70%) 13 (87%) 10(62.5% ) 7 (44%)
Gestation (weeks) 35 (34-37) 36 (32-37) 35 (35-37) 35 (32-35) t
Systolic BP (mmHg) 120 (110-130) 160 (150-169) Î 110(110-120) 116(110-120)
Diastolic BP (mmHg) 75 (70-80) 100 (95-105) 70 (60-80) 70 (60-80)
Booking systolic (mmHg) 120 (112-126) 117(102-126) 118 (110-126) 110(98-120 .7)
Booking diastolic (mmHg) 71 (66.2-77.2) 70 (66-76.5) 64 (60-73) 60 (60-69.2)
Gestation o f  delivery (wks) 39 (38-40) 36 (33.7-37) 40 (39-40) 37 (35-38) Î
Birthweight centile 50 (30-75) 25 (8.25-50) ’i 40 (10-60) 2.5 (1-10):];
Caesarean Section 20% 50% t 9% 50% :j:
All values are medians (interquartile ranges). Statistical analysis performed using 
Mamr-Wlritney U test and Chi-squared test. PE = Pre-eclampsia. BMI = Body 
Mass Index. BP=blood pressui’e. Statistical comparison of PE versus control and 
lUGR versus control: * p<0.1, *{’ p<0.05, $ p<0.001
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Pre-eclampsia
Results of fasting plasma lipoproteins, leptin, IL-6, CRP, insulin HbAlc, and 
soluble adhesion molecule concentrations are displayed in Table 2.
Metabolic parameters
Fasting plasma triglyceride and VLDL-C concentrations in the pre-eclamptic 
women were significantly higher than controls, as was fasting leptin, which was 
twice as high in pre-eclamptic women as compared with controls ( P<0.0001) 
(Table 2). Despite this, there was no significant difference in fasting insulin 
concentration between women with PE and controls. These differences persisted 
after adjustment for differences in age, parity and smoking history.
Inflammatory parameters
IL-6 concentration and adhesion molecules, sVCAM-1 and E-selectin were 
significantly gi'eater in PE women as compared with controls. Again these 
differences persisted after correction for age, parity and smoking history. Using 
univariate analysis, log leptin was found to correlate with log sVCAM-1 
concentrations (i-=0.54, p=0.036), and log IL-6 with log e-selectin (r==0.66, 
p=0.014) both independently of BMI (Leptin T=4.18, p=0.001; IL-6 T=2.80, 
p=0.019). No relationship existed between leptin and adhesion molecules in the 
control subjects (r=-0.102, p=0.59).
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RESU LTS Control
(n=30)
PE
(n=15)
P value A djusted  
P values
Lipoproteins
Cholesterol (mmol/l) 6.48 (5.68-7.28) 6.15 (5.3-7.65) 0.92 0.92
Triglyceride (mmol/l) 2.38 (2.05-2.95) 3.2 (2.75-4.75) 0.002 0.001
VLDL-C (mmol/l) 0.60 (0.34-0.85) 0.85 (0.65-1.15) 0.02 0.03
LDL-C (mmol/l) 4.05 (3.49-5.08) 3.5 (3.05-4.65) 0.31 0.51
HDL-C (mmol/l) 
Inflam m ation
1.55 (1.40-1.80) 1.55 (1.25-1.8) 0.89 0.85
Leptin (ng/ml) 40.5 (22.5-57) 74 (55.6-95) 0.0001 0.001
IL-6 (pcg/ml) 2.40 (1.76-3.09) 3 .37(1 .7-8 .5) 0.03 0.02
CRP (mg/ml) 2.74 (1.53-4.36) 3 .45(1 .95-6 .4) 0.30 0.21
VCAM-1 (ng/ml) 330(249-391) 431 (321-526.3) 0.02 0.02
ICAM -l (ng/ml)
219 (179-235)
233.9 (168-258) 0.67 0.85
E-selectin (ng/ml) 
Insulin sensitivity
51.3 (30.8-71.8) 55.98 (41-74.2) 0.15 0.06
Insulin (mu/1) 9 .8 (5 .6-21 .2) 14.5 (9.5-35) 0.09 0.21
H b A lc (%) 4.6 (4.3-4.7) 4.6 (4.5-4.9) 0.15 0.12
Table 2: Metabolic, and inflammatory parameters in pre-eclampsia.
A ll values are medians, (interquartile ranges). Statistical analysis performed using Mann-Whitney 
U test. PE = pre-eclampsia. VLDL-C = Very Low Density Lipoprotein Cholesterol. LDL-C = Low  
Density Lipoprotein Cholesterol. HDL-C = High Density Lipoprotein Cholesterol. H bA lc =  
Glycosylated Haemoglobin. IL= interleukin, CRP = C-reactive protein. ICAM = Intercellular 
adhesion molecule. VCAM = vascular cellular adhesion molecule. P values adjusted for 
differences in age, parity and smoking history.
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Endothelial dependent vasodilatation
Twelve of the PE women, with a median BMI of 26 (IQ range 23.5-27.8), had 
perfusion measurements performed. Of those twelve, seven were taldng anti­
hypertensives; six taking labetalol and one taldng nifedipine. Dose dependent 
perfusion response to ACH was not significantly different in controls as compared 
with pre-eclamptic women. (F igurel) Corrected area under the perflision.time 
curve (AUC) for ACH response was also calculated for each individual woman 
and used in simple linear regression. Perfusion results were examined in relation 
to anti-hypertensive use. The seven women taking anti-hypertensives were found 
to have significantly worse endothelial dependent perfusion responses 
(ACH/AUC) than women not taking drugs (10304 (4727-16281) versus 23737 
(13778-35039) PU MQ.min, p = 0.05). Both systolic and diastolic blood pressures 
were found to correlate inversely with endothelial dependent perfusion responses 
(ACH/AUC). (Systolic BP v ACH: r = -0.721, p = 0.008; Diastolic BP v ACH: r -  
-0.571, p = 0.05).
Endothelial independent vasodilatation
There was no significant difference observed between control and pre-eclamptic 
women for dose dependent perfusion responses to SNP (P=0.69).
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Figure 1: E ndothelial dependent (A C H ) vasodilatation.
Endothelial dependent (ACH) vasodilatation. Dose dependent perfusion response 
to ACH in control women (n=30, u), pre-eclamptic (n=12, v) and intrauterine 
growth restriction (n=16, a). Data are mean +/- standard error (SEM). Control 
versus lUGR: P < 0.01; control versus pre-eclampsia; P =  0.5, 2-way ANO VA .
Intra-uterine grow th restriction
Metabolic and Inflammatory parameters
LDL-C concentrations were significantly lower (3.0 (2.44-3.95) vs 4.0 (3.75-4.76) 
mmol/1, p=0.008) in the women with lUGR in comparison to controls follow ing  
adjustment for differences in parity, gestation and smoking history (T able 3). 
Leptin was increased in the women with lUGR following similar adjustment but
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this did not achieve statistical significance (P=0.1). No other significant 
differences were seen between the groups. Leptin did not correlate with any 
adhesion molecules.
RESU LTS lUGR (11=16) Lean (n=16) P value Adjusted 
P value
Lipoproteins
Cholesterol (mmol/1) 5.62 (4.9-6.S) 6.35 (5.S-6.8) 0.03 0.254
Triglyceride (mmol/1) 2.27 (1.56-3.07) 2.2 (1.98-2.56) 0.79 NS
VLDL-C (mmol/1) 0.62 (0.5-0.95) 0.55 (0.34-0.7) 0.16 NS
LDL-C (mmol/1) 3 (2.44-3.95) 4.05 (3.7-4.76) 0.0019 0.021
HDL-C (mmol/1) 1.67(1.35-2.44) 1.725 (1.44- 0.95 NS
Inflammation
Leptin (ng/ml) 27.1 (15.1-70.8) 23.8 (13.2-35.2) 0.17 0.1
IL-6 (pcg/ml) 2.07 (1.22-4.3) 2.1 (1.73-2.85) 0.74 NS
CRP (mg/ml) 3.61 (2.22-5.3) 2.25 (0.92-3.65) 0.07 0.176
VCAM-1 (ng/ml) 323 (289-415) 321 (276.3- 0.66 NS
ICAM-1 (ng/ml) 202 189 0.6 NS
E-selectin (ng/ml) 47.5 55 0.07 0.04
Insulin sensitivity
Insulin (mu/1) 6.9 (3.8-15.5) 6.5 (4.6-9.7) 0.45 NS
HbAlc (%) 4.5 (4.3-4.Ô) 4.4 (4.2-4.7) 0.5 NS
Table 3: Metabolic, and inflammatory parameters.
A ll values are medians, (interquartile ranges). Statistical analysis performed using Mann-Whitney 
U test. PET = pre-eclampsia. VLDL-C = Very Low Density Lipoprotein Cholesterol. LDL-C =  
Low Density Lipoprotein Cholesterol. HDL-C = High Density Lipoprotein Cholesterol. H b A lc  =  
Glycosylated Haemoglobin. 1L= interleukin, CRP = C-reactive protein. VCAM = vascular cellular
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adhesion molecule. Adjusted P value ^ adjustment for BMI, age, parity, gestation and smoking 
history. NS =  not significant.
Endothelial dependent vasodilatation
Dose dependent perfusion response to ACH was significantly greater in women 
with lUGR (BMI 22kg/m^) as compared with overweight controls (BMI 
26kg/nf). (Figure 1; P < 0.01)
Endothelial independent vasodilatation
There were no significant differences in dose -dependent perfusion response to 
SNP observed between women with pregnancies complicated with lUGR and 
controls (p = 0.5).
Discussion
This is one of the first studies to examine metabolic, inflammatory and vascular 
fimction simultaneously in groups of healthy pregnant women, women with pre­
eclampsia and women with lUGR. We demonstrate significantly elevated 
triglyceride and VLDL-C concentrations in pre-eclamptic women compared to 
BMI matched controls. By comparison, women with lUGR alone had a specific 
reduction in LDL-C concentrations, confirming our earlier report. We also 
noted a 4 unit lower median first trimester BMI in women who went on to develop 
a growth-restricted fetus as compared to those who developed PE (lUGR: 22.2 
(20-25.4) kg/nf Vs PE: 26(23.5-27.8) kg/m^, p=0.044). This 17% gi'eater total 
body weight in women destined for PE may explain in part why systemic effects 
occur in PE but not those with lUGR alone. For example, one may speculate that
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molecules liberated from a hypoxic placenta require the additional bui'den of a 
high maternal adipocyte mass to express their systemic influence to the full.
Leptin effects
Leptin concenti'ation was nearly double in women with PE compared to BMI 
matched controls, suggesting elevation independent of total adiposity. Women 
with lUGR when considered in relation to BMI matched controls, had a trend 
towards a small elevation in leptin concentrations (27.1 (15.1-70.8) vs 23.8 (13.2- 
35.2) ng/ml, p = 0.001). Leptin is a 161cDA adipocyte-derived protein that plays 
an important role as an endocrine hormone regulating adipose tissue mass. Leptin 
is also manufactured in the placenta and has recently been identified as an 
angiogenic gi’owth factor in animal models. Therefore its production by the 
placenta may play a role as a paracrine growth factor stimulating 
neovascularisation. Other groups have confirmed oui' findings of elevated 
concentrations of leptin in pre-eclamptic pregnancies and this elevation pre­
dates the clinical signs of pre-eclampsia perhaps secondary to ischaemia. In 
support of this, upregulation of leptin production in cultuied BeWo cells have 
been demonstrated in response to hypoxia (Figure 2).
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Figure 2 Potential m echanism s by w hich an excessive elevation in placental and 
potentially peripherally derived maternal leptin may effect the clinical syndrome 
o f  pre-eclampsia. A failure o f  this response to placental ischaem ia may favour the 
clinical picture o f  lUG R, with maternal sparing from system ic effects.
The potential link between leptin and the maternal syndrome o f  pre-eclam psia is 
unclear. A s described above, leptin plays a role as an angiogenic growth factor
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The potential link between leptin and the maternal syndi’ome of pre-eclampsia is 
unclear. As described above, leptin plays a role as an angiogenic growth factor 
and Cao et al have recently demonstrated in mice that new, leptin induced 
capillaries are fenestrated, with a rapid increase in vascular pemieability observed 
in response to intradermal leptin administration. Certainly the clincial features of 
severe pre-eclampsia such as proteinuria, pulmonary and peripheral oedema, are 
thought to represent an increase in capillary permeability. In the leptin deficient 
ob/ob mouse, abnormalities in endothelial dependent vasodilatation are observed 
which administration o f leptin or pre-incubation of endothelial cells with leptin 
can correct. Therefore it may be that leptin acts somehow to produce 
endothelial dependent vasodilatation and the impaired vasodilatory effect 
observed in pre-eclampsia may be secondary to an exaggerated leptin resistance, 
such as that seen in the obese and/or insulin-resistant individual. In addition leptin 
induced angiogenesis may increase fatty acid oxidation in an attempt to maintain 
an appropriate balance between blood supply and fat deposits. Tlris was 
demonstrated by Yamagishi et al in association with induced reactive oxygen 
species in cultured endothelial cells. It is well established that oxidised molecules 
are associated with endothelial cell activation and damage  ^ and this process is 
also implicated in the pathophysiology of pre-eclampsia In support of this, we 
have demonstrated a significant relationship between leptin and the soluble 
marker of endothelial activation VCAM-1 (leptin versus log VCAM: r = 0.284, p 
= 0.028; adjustment for BMI: p=0.022) We also demonstrate that although a small 
elevation in concentration of leptin in women with lUGR was noted, this was
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such as leptin. Studies evaluating cord plasma concentrations of leptin have 
suggested that leptin concentration, when considered per kg. fetal weight, is 
significantly greater in growth restricted fetuses, perhaps consequent to abnormal
placentation and resultant hypoxia. 221 222 223 We noted a significant inverse
relationship between maternal third trimester leptin and subsequent birth centile 
of offspring (r = -0.40, adjusted p=0.016) (Figure 3). Potential mechanisms 
relating to this association are unclear although it is relevant that leptin enliances 
fatty acid oxidation, and thus efficient utilisation of maternal fatty acid stores 
(Figure 2). Therefore it may be that lUGR results partly due to an inadequate 
maternal response to placental ischaemia.
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Figure 3: Relationship between maternal log transfonned concentrations o f  leptin in third
trimester and birth centile for gestational age, appropriate for sex o f  offspring.
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Figure 3: Relationship between maternal log transformed concentrations o f  leptin in third 
trimester and birth centile for gestational age, appropriate for sex o f  offspring.
Inflammation
We observed an inflarmnatory phenotype with elevated circulating IL-6 
concentrations in women with PE, but not in lUGR. VCAM-1 and E-selectin are 
glycoproteins expressed on the endothelial cell surface in response to an 
inflammatory, usually cytoldne or oxidant mediated challenge. Their puiposes are 
to recruit leukocytes and mediate leukocyte rolling and platelet-leukocyte 
aggregation, resulting in endothelial dysfunction and increased capillary 
permeability. VCAM-1 and E-selectin were significantly elevated in pre­
eclamptic women as compared with obese controls. In contrast, in women with 
lUGR, such parameters were not elevated and indeed after adjustment for 
differences in demographic factors, E-selectin concentrations in the women with 
lUGR were significantly less than controls (p=0.04). These data further support 
the hypothesis o f an absence of maternal systemic inflammation in women with 
lUGR.
Evidence from existing literature demonstrates activated inflammatory cells such 
as gi’anulocytes and monocytes in women with pre-eclampsia with release of pro- 
inflammatory cytokines such as TNFa, IL-6 and soluble phospholipase A2. 
Human blood leukocytes express the leptin receptor, and the predominant leptin 
receptor-expressing cell type is the monocyte. In vitro, leptin has been shown to 
modulate the iimiiune response, inducing the production of inflammatory 
cytokines, particularly TNF-a and IL-6. (Figure 2) Also, an increase in serum
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concentrations of both VCAM-1 and ICAM-1 have been demonstrated previously 
1 0 8 109 Y/ et al noted a similar pattern of elevated E-selectin and VCAM-1 
but not ICAM-1 in their investigation of serum from pre-eclamptic women. Greer 
et al also noted a significant correlation between IL-6 and VCAM-1 (r=0.539, 
p<0.005) in women with pre-eclampsia. Tins relationship was confimied in our 
subjects (log IL-6 versus log VCAM; r = 0.268, p = 0.038). The increase in 
VCAM is of particular interest in the metabolic context as VCAM is critical for 
monocyte activation to macrophages. The combination of monocyte activation 
and high triglyceride levels will lead to lipid laden maiTophages in the vessel wall, 
which is a feature of the characteristic vascular lesion seen in pre-eclampsia.
In-vivo endothelial function
We did not demonstrate in-vivo evidence o f micro vascular dysfunction in women 
with pre-eclampsia. To our laiowledge, all previous ex vivo studies demonstrating 
endothelial dysfunction in PET using dynamic tests have not considered nor 
controlled for BM f^ By contrast, in-vivo findings have
consistently failed to demonstrate endothelial dysfunction in PET, and in general 
have controlled for BMI. Therefore, previous ex-vivo evidence of endothelial 
dysfunction in PET may reflect the inadvertent use of a lean control group.
These findings are obviously somewhat confusing and may be inteipreted in 
different ways. Firstly, it may be that observed microvascular endothelial 
dysfunction may relate predominantly to total adiposity. Obesity is a risk factor
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for cardiovascular disease and particularly pre-eclampsia and is associated 
with hyperleptinaemia, deranged lipid profiles, insulin resistance and
inflammation
Secondly, elevation in leptin in pre-eclamptic women is much greater than that 
explained by raised BMI alone and placental ischaemia has been implicated. As 
discussed above leptin may increase capillary permeability as seen in severe pre­
eclampsia, independently of impaired endothelial dependent vasodilatation. In 
support of this, a recent study by Wang et al has demonstrated increased 
endothelial monolayer permeability in cells from pre-eclamptic women. 
(Figure 2) Our teclmique for microvascular assessment of LDI in combination 
with iothophoresis of ACH and SNP does not detect endothelial penneability.
A third explanation may be that the technique of LDI in combination with 
iontophoresis does not examine the biologically appropriate vascular beds. We 
have examined the skin microvasculature on the assumption that these small 
vessels represent resistance vessels that in other experiments out-with pregnancy 
have been implicated in the development of cardiovascular disease. Reduced 
responsiveness to iontophoretic administration of ACH has been observed in 
diabetes and hypercholesterolaemia and in both these conditions there
is a parallel reduction of the ACH response in the forearm circulation (a 
predominantly skeletal muscle vascular bed) assessed by venous occlusion 
plethysmography. These observations were independent of BMI and
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therefore in gi'oups with elevated vascular risk this technique is adequate to 
demonstrate an effect. Vollebregt et al also failed to demonstrate endothelial 
dysfunction in pre-eclamptic women using laser Doppler fluxmetry but did 
demonstrate impaired local veno-arteriolar reflex in the capillaries of the skin 
It may be that in-vivo, the capillary beds, rather than the arterioles, manifest the 
increased endothelial permeability and dysfunction associated with the clinical 
syndrome of pre-eclampsia.
Finally, the syndrome of pre-eclampsia is a notoriously heterogeneous condition 
with many studies diluted by differing definitions of the condition. It has been 
suggested that mild disease at term is significantly different from severe 
premature disease requiring interventional delivery. Due to the bulky nature of 
our equipment, subjects had to come to the test area rather than the investigation 
being performed at the bedside. As a result, a less severe group o f women were 
examined. The relationship between gestation of onset of disease and the response 
to ACH as determined by the area imder the perfusion time curve (AUC), 
demonstrated an indirect correlation, that is the worst endothelial dependent 
responses were associated with earliest gestation of disease onset, (r = 0.513, p =
0.088) This may imply that our pre-eclamptic cohort may be diluted to some 
degree, with our median gestation of testing being 36weeks. The fact that over 
half our pre-eclamptic subjects were taking antihypertensives did not seem to 
adversely affect our perfusion results. One may predict that the more clinically 
severe cases would be those women where anti-hypertensives were necessary and
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this is reflected in onr results with the seven women talcing medication 
demonstrating significantly worse responses to ACH. Also despite a significant 
proportion of the women taking anti-hypertensives, the blood pressure at the time 
of testing was found to demonstrate a significant inverse conelation with ACH 
response.
Therefore, in summary, we demonstrate elevated triglyceride and near double 
leptin levels in PE independent o f BMI. By contrast, BMI and lipid (LDL-C) 
concentrations in women with lUGR were significantly reduced, suggesting a 
possible protective role for “leanness” with regard to maternal systemic effect. 
Women with PE but not lUGR also demonstrate elevations in circulating cytokine 
and adliesion molecules. Despite these findings, in vivo evidence of impaired 
endothelial-dependent vasodilatation in skin microvasculature was laclcing in 
women with PE in comparison to a BMI matched group of healthy women. We 
propose that demonstrable in-vivo endothelial dysfunction may not represent the 
entire pathophysiological mechanism of PET and inflammation and increased 
capillary permeability, perhaps secondary to massively elevated levels of 
placentally derived leptin, may result in much of the clinical syndrome of PET 
(F igure 2).
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C h a p ter  7
Pre-eclampsia and maternal coronary heart disease may 
be linked through inflammation and insulin resistance.
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Introduction
Epidemiological studies have recently demonstrated a relationship between pre­
eclampsia and an increased risk of maternal coronary heart disease in later life.
However, there are few data available to explain any underlying mechanism. 
Pre-eclampsia shares common pathological features with atherosclerosis, both 
biochemical (insulin resistance, hypertryglyceridaemia, thrombotic and pro- 
inflammatory changes) and biological (endothelial dysfunction) ^28 ii3^
Thus common risk factors, either genotypic or phenotypic, may underlie both pre­
eclampsia and coronary heart disease.
Only one small study examining insulin sensitivity has assessed women at a 
considerable interval (17 years) after a pre-eclamptic pregnancy; an age when risk 
factors for coronary heart disease may be more relevant. Furthermore, despite the 
predictive value of inflammatory markers for vascular disease in women there 
are limited data available in relation to women with previous pre-eclampsia, The 
endpoint of these metabolic and inflammatory disruptions is believed to be 
endothelial dysfunction and this has been proposed as a mechanism preceding the 
development of coronary artery disease. Endothelial dysfunction has been
demonstrated in vessels from pre-eclamptic women during pregnancy and recently 
Chambers et al demonstrated in-vivo, impaired endothelial function at least 3 
months (median 3 years) postpartum. Our aim in this study therefore was
firstly, to test the hypothesis that insulin resistance, inflammation, and 
hyperlipidaemia would persist in women with a history of pre-eclampsia up to 15-
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25 years following pregnancy and secondly that within this group there would 
exist demonstrable endothelial dysfunction.
Methods
This study was carried out in two sections. All work was performed according to 
the Declaration of Helsinld, approval was gi'anted by the institutional ethics 
committee and all patients gave written informed consent.
1. Indirect examination o f  cardiovascular risk factors
(serum lipids, markers o f  inflammation and glycaemic control)
Primigravidae delivering between 1975 and 1985 with proteinuric pre-eclampsia 
and controls, matched as a gi*oup for time since index pregnancy, parity and 
current body mass index, were identified from medical records. Forty women with 
a history of pre-eclampsia and 40 controls were recruited. Blood pressure, body 
mass index, and abdominal circumference were measured. Venous blood was 
taken after an overnight fast and analysis performed as previously described in 
preceding chapters.
2, Direct examination o f  cardiovascular risk factors,
(In-vivo microvascular function)
Of the original cohort, 10 cases and 10 controls were invited to re-attend for in- 
vivo assessment of microvascular endothelial function using laser Doppler 
perfusion imaging and iontophoretic administration of microvascular vasodilators
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acetylcholine (ACH; endothelial dependent) and sodium nitroprusside (SNP; 
endothelial independent) as previously described in chapter two. Units of 
perfusion were derived from multiplying the perâision.time integral by the 
resitance.time integr al as calculated by continous voltage monitorring as 
described on page 63. This group was selected by writing to the women who 
participated in part one of the study and inviting them to reply if  they were able to 
return for further examination. The first ten cases and controls to reply were 
investigated.
Statistical analyses
Dose response curves were expressed as means ± SEM and comparisons were by 
2-way ANOVA. Other data are expressed as medians with the interquartile range 
as the measure of variability. For these data the Mann Wlritney U test were used 
for comparisons between groups. Linear relationships between variables were 
examined using the Pearson correlation coefficient after normalising skewed 
variables by log ti'ansformation.
R esults
1. Indirect examination o f cardiovascular risk factors
(serum lipids, markers o f inflammation and glycaemic control)
The demographic details of these groups are demonstrated in Table 1.
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Characteristics
Age (years)
Time since index preg. (years) 
BMI (kg/nT)
Abdominal circ. (inches) 
Parity (1,2, >2)
Systolic pressure (mmHg) 
Diastolic pressure (mmHg) 
Smokers (%)
Hypertensive Rx 
Dyslipidaemia Rx 
Hormone Rx (HRT or 
contraception)
Menopausal (%)"'
Index pregnancy 
Age (years)
BMI (kg/nT)
Smokers (%)
Social class (DEPCAT score) 
Gestation at delivery (weeks) 
Birth centile (weeks)
PET group
N - 4 0
Control group
n - 4 0
P-value
43 (40-47) 
20 (17.5-22) 
27 (23-30) 
32 (30-36) 
12, 16, 12 
124 (114-136) 
83 (74-88)
9 (22.5%)
7 (17.5%)
2(5%)
13 (32.5%)
15 (37.5%)
24 (21.2-26) 
22 (21-24.5)
10 (25%)
4 (2-7)
36 (33.2-38) 
18(5.2-64.2)
44 (43-47) 
20 (17-23) 
26 (23-28) 
31.5 (28.7-34) 
12, 16, 12 
116(108-130) 
76 (69-83) 
6(15%) 
2(5%) 
0 (0%) 
6(15%)
7 (17.5%)
25 (21-27) 
22 (20-23)
11 (27.5%)
4 (2-6)
40 (38-41) 
60 (27.5-90)
0.5
0.96
0.5
0.46
0.94*
0.086
0.035
0.39*
<0.08*
0.152*
0.008*
0.045
0.83
0.02
0 .8*
0.46
<0.001
0.006
Table 1. Demographic characteristics (Pait 1) All values are medians (interquartile ranges). Statistical analyi is 
perfonned using Mann-Whitney U test, Chi-squared test. PET = Pre-eclampsia. BMI =  Body Mass Index. 
Preg = pregnancy, circ = circumference. HRT = hormone replacement therapy.
There were no significant differences in age, BMI, abdominal circumference, 
smoking status and parity between the two groups at the time of testing. Although 
normotensive, the women with a past history of pre-eclampsia were found to have 
higher blood pressure than the controls. (124/83 versus 116/76 mmHg). Of 
interest, a greater proportion of the women with a past history o f pre-eclampsia
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were taking anti-hypertensive, lipid-lowering and hormonal therapy 
(contraceptive and hormone replacement therapy) at the time of testing. In 
addition, despite similar ages, a significantly gi'eater proportion of the women 
with a past history of PE were menopausal (P==0.045). Two of the women with a 
past history of pre-eclampsia were diabetic. With regards to the index pregnancy, 
the women with pre-eclampsia had a significantly gi'eater BMI (p=0.02), earlier 
gestation of delivery (<0.001) and gave birth to babies with a lower birth weight 
centile (0.006). The social class distribution was significantly different at the time 
of the index pregnancy.
There was no difference in fasting lipid concentrations. (Table 2) VCAM-1 and 
ICAM-1 concentrations were significantly higher in the pre-eclampsia group, and 
the difference in ICAM-1 but not VCAM-1 concentrations persisted after 
adjustment for antihypertensive, lipid-lowering, and hormonal therapy. (ICAM: 
T=-2.77, p=0.007; VCAM: T=-1.67, p=0.1). The women with a past histoi'y of 
pre-eclampsia had higher lasting insulin and significantly gi'eater HbAlc 
concentrations (p=0.004). Difference in HbAlc concentrations also persisted after 
adjustment for the above factors (T=-2.65 p=0.01) and on re-analysis after 
exclusion of the two diabetic women the statistical difference in HbAlc 
concentrations persisted (median 4.7% versus 4.5%, p=0.01). Smoking influenced 
ICAM concentration but the relationship with pre-eclampsia persisted on logistic 
regression (T=-2.15, p=0.035). Within the post pre-eclamptic women, log VCAM- 
1 correlated with BMI (r -  0.4, p=0.009), log leptin (r^O.33, p=0.04), and log
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HBAlc (r=0.44, p=0.005). Log ICAM-1 correlated indirectly with log HDL (r
0.38,p=0.01).
Variable PET group
n=40
Control group
n~40
P-
value
Lipids
Cholesterol (inmol/L) 5.2 (4.4-5.Ô) 4.7 (4.0-5.6) 0.26
Triglyceride (iinnol/L) 1.0 (G.7-1.3) 0.9 (0.7-1.2) 0.79
VLDL-C (inmol/1) 0.35 (0.2-0.4) 0.36 (0.2-0.5) 0.98
LDL-C (inniol/1) 2.85 (2.5-3.6) 2.81 (2.1-3.6) 0.41
HDL-C (inmol/1) 1.55(1.3-1.8) 1.45(1.2-1.8) 0.38
Inflammation
ICAM-1 (ng/ml) 351 (249-449) 243 (205-315) 0.002
Nonsmokers 337 (235-393) 220 (204-268) 0.004
Smokers 452 (356-583) 336(241-568) 0.26
VCAM-1 (ng/ml) 390 (322-460) 342 (272-417) 0.038
E-selectin (ng/ml) 59.6 (38.2-77.4) 49.8 (32.5-75) 0.44
CRP (mg/L) 1.42 (0.7-4.3) 1.19(0.6-2.8) 0.25
Metabolic
HBAlc (%) 4.7 (4.4-5.2) 4.5 (4.4-4.6) 0.004
Insulin (mlU/L) 8.35 (5.3-12.8) 6.4 (4.5-9.3) 0.08
Leptin (ng/ml) 33.7(19.4-51.2) 25.2(18-37) 0.13
Table 2 Inflammatory and metabolic markers (Part 1) All values are medians (interquartile 
ranges). Statistical analysis perfomied using Mann-Whitney U test. ICAM =  intracellular adhesion 
molecule. VLDL-C = Very Low Density Lipoprotein Cholesterol. LDL-C = Low Density  
Lipoprotein Cholesterol. HDL-C -  High Density Lipoprotein Cholesterol. VCAM = vascular 
cellular adhesion molecule. CRP = C-reactive protein. H bA lc = glycosylated haemoglobin.
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2) Direct examination o f  cardiovascular risk factors. (In-vivo microvascular 
function)
Demographic details of the subgi’oup investigated are displayed in table 3. There 
were no significant differences in age and BMI at the time of testing, however the 
post pre-eclamptic group did have a significantly higher diastolic blood pressiu'e 
(84 V 68 mmHg, p =0.007) and a greater proportion of women taking 
antihypertensive therapy. As before, the BMI at the time of index pregnancy was 
gi'eater in the pre-eclamptic women. (23 v 20 kg/nf)
Characteristics PET group Control group P-value
N=10 n-10
Age (years) 44.5 (38-47) 46 (42-48) 0.4
Time since index preg. (years) 22.5 (16-23) 20 (18-24) 0.7
BMI(kg/nT) 24(21-28) 23 (22-26) 0.6
Abdominal circ. (inches) 29 (28-32) 29.5 (26-32) 0.9
Systolic pressure (mmHg) 130 (117-136) 120 (98-131) 0.16
Diastolic pressure (mmHg) 84 (77-87) 68 (60-77) 0.007
Smokers 2 2 0.98*
Hormone therapy 5 3 0.463*
Antihypertensive therapy 3 0 0.07*
Index pregnancy
Age (years) 24.5 (21-30) 25 (21-30) 0.7
BMI (kg/nd) 23 (21-24) 20 (19-22) 0.038
Smokers 1 3 0.2*
Gestation at delivery (weeks) 36 (32-38) 39 (38-40) 0.01
Birth centile (weeks) 17 (4-69) 60(34-85) 0.13
T able 3. Demographic characteristics (Part 2) All values are medians (interquartile ranges). Statistical analysis
perfonned using Mann-Whitney U test, Chi-squared test. PET = Pre-eclampsia. BMI = Body Mass Index.
Preg = pregnancy. Circ ^  circumference
163
Endothelial dependent vasodilatation
Dose dependent perfusion response to ACH was significantly greater in the 
control as compared with post pre-eclamptic women (Figure lA , P =0.005).
160 0
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F igure 1: Endothelial dependent (ACH) vasodilatation.
A) Dose dependent perfusion response to ACH in post pre-eclamptic women (n=10; ♦) and control 
women (n=10; ■). Data are mean +/- standard error (SEM). P = 0.005, 2-way ANOVA.
Corrected area under the perfusion.time curve for ACH response was also 
calculated for each individual woman and reflected these observations with a 
significantly smaller response seen in the women with a past history o f  pre­
eclampsia. (9358 (4020) v 14979 (6530) PU MQ.min, p = 0.044 Figure IB) This 
relationship persisted after correction for smoking history, overall parity, age,
BMI and blood pressure at the time o f  testing. However after adjustment for 
differences in those women taking antihypertensives, the significance was reduced 
(T=1.86, p=0.08).
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Figure 1: Endothelial dependent (ACH) vasodilatation.
B) Boxplot o f  area under the perfusion.time curve (AUC) for response to ACH in post pre­
eclamptic women (n=10) and control women (n=10). P = 0.044, students t-test
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Endothelial independent vasodilatation
Dose dependent perfusion response to SNP was significantly greater in the control 
as compared with post pre-eclamptic women (Figure 2A, P=0.023).
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Figu re 2: Endothelial independent (SNP) vasodilatation
A) Dose dependent perfusion response to SNP in post pre-eclamptic women (n=10; ♦) and control women 
(n=l 0; ■). Data are mean +/- standard error (SEM). P = 0.023, 2-way ANOVA.
Corrected area under the perfusion.time curve for SNP response was also 
calculated for each individual woman and again showed a significantly smaller 
response in women with a past history o f  pre-eclampsia. (7861 (3676) v 12136 
(4620) PU MQ.min, p =  0.043 Figure 2B) Again, this relationship persisted after 
correction for similar demographic factors as described above, including those 
women taking hypertensive therapy.
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Figu re 2: Endothelial independent (SNP) vasodilatation
B) Boxplot o f area under the perfusion.time curve (AUC) for response to SNP in post pre­
eclamptic women (n=10) and control women (n=10). P = 0.043, students t-test.
Discussion
These data show for the first time that women with a past history of pre-eclampsia 
have increased plasma concentrations of the inflammatory markers, VCAM-1 and 
ICAM-1, 15 years or more after the index pregnancy compared to controls. We 
have also demonstrated, using a novel, non-invasive, in-vivo teclmique, impaired 
endothelial dependent vasodilatation in women with a past history of pre­
eclampsia. Chambers et al also examined these parameters in a group of women 
at least 3 months (median 3 years) postpartum. In concordance with our results, 
they did not identify any significant difference in lipids between the post pre­
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eclamptic women and controls but did not identify any elevation in concentration 
of adhesion molecules in women with a single episode of pre-eclampsia despite 
demonstrating, using a different in-vivo technique, impaired endothelial 
dysfunction. This may represent the short interval at which these factors were 
evaluated following the index pregnancy.
Adhesion molecules are expressed on the surface of vascular endothelial cells in 
response to inflammatory cytokines and are believed to encourage adhesion of 
circulating leukocytes and their subsequent trans-endothelial migration. This 
process is believed to be critical in the progi'ess of early atherogenesis and cross- 
sectional data suggest that soluble fomis of these proteins are elevated in patients 
with atherosclerosis. ICAM-1 in particular has recently been established to 
be independently predictive for coronary heart disease and fr om the 
Atherosclerosis Risk In Communities (ARIC) study, those with baseline 
concentrations of sICAM-1 in the highest quartile, when followed up for five 
years, were found to have a frve-fold increased risk of incident coronary heart 
disease (RR 5.5, 95%CI 2.5-12.2). These data are proposed to support the 
hypothesis that endothelial activation and damage, or “inflammation” occur early 
in the atherosclerotic process.
Women with a past history of pre-eclampsia also have gr eater insulin and H BAlc 
concentrations, confirming observations from an earlier report We also 
demonstrated in our population that concentrations of soluble VCAM-1 correlate
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with HBAlc and BMI. Seme et al demonsti'ated an inverse relationship between 
blood pressure and insulin sensitivity in the non-pregnant individual as well as a 
strong positive relationship between microvascular function and insulin 
sensitivity. Consequently, this group propose abdominal fat to be a source of free 
fatty acids (FFA) and cytokines, which are secreted into the circulation. These 
circulating factors would promote vascular inflammation and endothelial 
dysfunction, and result in insulin resistance and hypertension as described above. 
Certainly, the deleterious effect of FFA and cytokines on endothelial function has 
been demonstrated previously. * * One may hypothesise, therefore, that reduction 
in BMI, with consequent reduction in inflammation and improvement in insulin 
sensitivity may provide some hope of altering this predisposed risk of 
cardiovascular disease. Ziccardi et al have demonstrated in a group of obese pre­
menopausal women that weight loss over one year was associated with a 
reduction in inflammatory cytokine concentrations, a reduction in adhesion 
molecule concentrations including ICAM-1 and an improvement in endothelial 
dependent vascular function.
In conclusion therefore, these data suggest that the phenotype associated with pre­
eclampsia is linlced to novel mechanisms underlying coronary heart disease and 
may explain, in part, the epidemiological association between pre-eclampsia and 
coronary heart disease. This association may be genetically or phenotypically 
determined but evidence exists to suggest that such lifestyle modifications as 
weight loss may ameliorate this underlying cardiovascular disease risk.
169
C h a p ter  E ig h t
Conclusions
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The origins of atherosclerotic cardiovascular disease are believed to lie in the 
functionality o f the microvascular endothelium. These cells provide not only a 
structural role but they also act as a highly complex endocrine and paracrine 
organ. They produce many vaso-active substances, such as vasodilators, nitric 
oxide, the eicosanoids, particularly prostacyclin, and endothelial derived 
hyperpolarising factor, as well as the vasoconstrictor endothelin, all o f which play 
a role in the modulation of local and systemic blood flow and peripheral pressiue. 
However, the endothelium and its products also provide a protective function for 
the vessel wall, inliibiting platelet aggregation, smooth muscle cell migration and 
proliferation, adlresion molecule expression and consequently monocyte adhesion, 
thus inliibiting the development of tluombosis and atheromatous plaques. The 
disease process involved in the activation and eventual damage of this cell layer is 
believed to arise secondary to an inflammatory stimulus. Some individuals will 
inherit a genetic tendency to be more predisposed to the effects of inflammation or 
to be more “pro“inflammatory” either through oxidative processes or tluough their 
production of inflammatory molecules. Acquired factors, such as older age and 
obesity, as well as enviromnental factors, for example cigarette smoking or social 
deprivation, will also contribute.
Many of the clinical risk factors for cardiovascular disease in later life are also 
shared by cardiovascular disease in pregnancy; that is pre-eclampsia. 
Epidemiologically, a past history of a pregnancy affected by pre-eclampsia 
confers an elevated risk of premature development of ischaemic heart disease,
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hypertension and type two diabetes. At present, the exact mechanisms involved in 
the pathophysiology of pre-eclampsia are poorly understood. Also, little is Imown 
concerning the mechanisms involved in the association between such 
complications of pregnancy and cardiovascular disease in later life. Endothelial 
cell dysfunction would seem a reasonable hypothesis linldng these two conditions 
and this has been demonstrated in vitro in vessels and cells from pre-eelamptic 
women.
Therefore, in chapter two and three we described how we devised a robust 
protocol for the in-vivo assessment o f microvascular endothelial cell function, 
which could be utilised for the examination of pregnant women. Thus this 
technique required to be safe and well tolerated. We used laser Doppler imaging 
in combination with iontophoretic topical dmg delivery for the assessment of the 
skin microvasculature. In chapter two we focused on drug delivery and noted that 
quantity of drug delivered is not only proportional to the amount of charge 
applied, as suggested from previous literatui’e, but also to the individual electrical 
properties o f the skin. We introduced continuous voltage monitoring during the 
procedure, which allowed us to calculate resistance using Ohm's law. We were 
able to demonstrate a strong inverse relationship between skin resistance and 
vasodilator effect and therefore were able to develop a correction factor, by 
multiplying the perfusion.time integral by the reciprocal of impedance or more 
simply by resistance.time integral. We studied vascular responses to the 
vasodilators, ACEI (endothelial dependent) and SNP (endothelial independent)
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and identified that response to ACH is unlikely to be mediated by prostanoids as 
vasodilatation secondary to this drug was not reduced by administration of cyclo- 
oygenase inhibition.
In chapter three we focused on the elimination of electrically-induced hyperaemia. 
Iontophoresis or essentially the passage o f a small electrical charge through the 
micro vasculature can result in a hyperaemic response independent of any drug 
delivery and therefore this would complicate the inteipretation of any results. 
Again the use of continuous voltage monitoring enabled us to realise that the 
production of such a response is associated with high voltage secondary to high 
resistance or current. These situations can result consequent to use of a non- 
conductive vehicle such as distilled water or large amounts of charge either by 
using high currents or very small areas of current application. Therefore we were 
able to show that drugs in solution were associated with low voltages and 
therefore were unlikely to be complicated by this effect. We identified that use of 
large drug chambers, low charges and an ionic solution such as 0.5% NaCl for the 
vehicle, produced no electrically induced hyperaemia and was also associated 
with low voltages. We also identified that this effect appeared to be, at least in 
part, prostaglandin dependent, as cyclo-oxygenase inhibition reduced the 
response.
We then went on to utilise this now robust and well-tolerated in vivo technique for
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the examination of microvascular function in pregnant women. As discussed 
above many clinical risk factors are shared between vascular diseases of 
pregnancy and later life. In chapter four and five, we examined pregnant women 
with such clinical risk factors in an attempt to elucidate potential mechanisms 
predisposing these women to an elevated risk of pre-eclampsia.
In chapter four we examined obese pregnant women in relation to lean. Out-with 
pregnancy, adipose tissue takes on a dynamic role, releasing many inflammatory 
molecules such as cytokines and free fatty acids laiown to result in microvascular 
dysfunction. We demonstrated that these associations persist in pregnancy, despite 
the beneficial effects of other pregnancy associated changes with regards to 
vascular function. Our data showed that obesity in pregnancy is associated not 
only with marked hyperinsulinaemia (without necessarily glucose dysregulation) 
and dyslipidaemia (elevated triglyceride an reduced HDL-C), but also impaired 
microvascular function, higher blood pressure and inflammatory up-regulation 
(elevated IL-6 and CRP concentrations). Such a spectrum of risk factors may 
contribute to maternal complications in obese women.
In chapter five we examined healthy women and women with type 1 diabetes in 
the third trimester of pregnancy and again in the postpartum period. 
Microvascular function in both controls and diabetic women improved during 
pregnancy although responses in women with diabetes were significantly inferior
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to controls during both these periods despite similar lipoprotein profiles. 
Moreover, in both groups the magnitude of improvement in ACH response with 
pregnancy correlated inversely with responses postpartum. The difference in 
vascular responsivity between cases and controls was significantly attenuated by 
adjustment for differences in HbAlc, but not CRP concentrations in the two 
groups. These data suggest that pregnancy enlrances microvascular function, 
conferring the greatest improvement for those individuals with the worst 
microvascular function out-with pregnancy. However, in women with diabetes 
such improvements are insufficient to attain responses seen even in healthy, non­
pregnant women. This suggests a persistent vascular defect in young women with 
type I diabetes that may contribute to adverse pregnancy outcome. Our data 
suggest a role for the chronic effects of hyperglycaemia in the impaired vascular 
responsiveness in such women.
As described previously, pre-eclampsia is proposed to arise secondary to an 
inflammatory insult, activating and damaging endothelial integiity. One 
hypothesis for the source of this insult is a factor released into the maternal 
systemic circulation from a poorly implanted and ischaemic placenta. In chapter 
six our technique for microvascular assessment did not confirm endothelial 
dysfunction as the main pathological factor in the mechanism of pre-eclampsia. 
We noted a stepwise decrease in endothelial function from lean (mean BMI 22 
kg/m^), to pre-eclamptic (mean BMI 26 kg/nf) although worst results were seen 
in obese normotensive women (mean BMI 32 kg/m^). We demonstrated elevated
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concentrations of both fasting leptin and triglyceride in pre-eclamptic women in 
relation to obese controls, suggesting this effect to be independent of BMI. As 
suspected women with lUGR were found to have normal endothelial function 
comparable with lean individuals and had a significantly lower BMI at booking 
than pre-eclamptic women. We also observed reduced LDL-C concentrations in 
women with lUGR as compared with pre-eclamptic women and controls. This 
may suggest a potential protective role for “leanness” with regard to maternal 
systemic effect. We noted a stepwise increase from lean to obese to pre-eclamptic 
in the concentration of the inflammatory cytokine IL-6 consistent with the 
inflammatory theory of pre-eclampsia. In support of this we demonstrated a 
significant elevation in the circulating concentrations of the adhesion molecules, 
VCAM-1 and E-selectin in the pre-eclamptic cohort as compared with obese 
controls. We propose that demonstrable in-vivo endothelial dysfunction as 
measured by this teclinique, may not represent the entire pathophysiological 
mechanism of PET. However, inflammation has been indirectly demonstrated by 
elevated concenfrations of soluble circulating markers and IL-6. We propose that 
secondary to placental hypoxia, massively elevated levels of placentally derived 
leptin and inflammatory cytokines may increase maternal systemic capillary 
permeability and result in some of the clinical syndrome of severe pre-eclampsia. 
In the obese individual this may be exaggerated by an increased adipocyte mass 
with elevated inflammatory cytokines, fr ee fatty acids and oxidated lipoproteins, 
whereas in the lean individual with lUGR, the placental production of 
inflammatory molecules has less of a maternal systemic insult. Vascular
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dysfunction resulting in hypertension and vascular lability may be demonstrable 
in other vascular beds. Therefore, in-vivo methods of microvascular function 
assessment, using LDI and iontophoresis, is not a sensitive or specific test for the 
diagnosis or prediction of pre-eclampsia and will have little impact in clinical 
management of this condition.
In chapter seven we demonshated that healthy women with a past history of pre­
eclampsia, 15-25 years after the index pregnancy, have increased plasma 
concentrations of the adhesion molecules and markers of endothelial damage, 
VCAM-1 and ICAM-1. We also demonstrated impaired endothelial dependent 
vasodilatation in women with a past history of pre-eclampsia. These data suggest 
that the phenotype associated with pre-eclampsia is linlced to novel mechanisms 
underlying coronary heart disease and may explain, in part, the epidemiological 
association between pre-eclampsia and coronary heart disease. This association 
may be genetically or phenotypically determined but evidence exists to suggest 
that such lifestyle modifications as weight loss and regular exercise may improve 
endothelial function and metabolic factors such as insulin sensitivity and therefore 
may ameliorate this underlying cardiovascular disease risk.
Therefore in summary, we have developed a robust protocol for the in-vivo 
assessment of cutaneous microvascular function. This teclmique has not 
confirmed previous in-vitro observations that pre-eclampsia arises secondary to
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endothelial dysfunction and in fact, obese women had most severe alterations in 
microvascular function and remained normotensive. Certainly endothelial 
dysfunction contributes to pre-eclampsia to some extent and is implicated by 
elevated concentrations of circulating soluble adhesion molecules. Also we have 
identified that this state does persist into later years and good evidence exists 
outwith pregnancy to suggest that this phenotype is associated with a significantly 
elevated risk of ischaemic heart disease. It may be that women with a pre-existing 
vascular and/or inflammatory abnormality, which could be either genetically 
inlierited or acquired thiough “intra-uterine fetal programming” or environmental 
factors, going into pregnancy, have a greater chance of initial problems with 
placental implantation and then maternal systemic effect resulting in pre- 
eclampsia. Such groups are those women, as described above, with obesity or 
diabetes. Thereafter, further inflammatory insult arises from the ischaemic 
placenta and a state, similar to severe sepsis, arises with vascular dysfunction, 
increased capillary permeability and coagulation activation. This may be mediated 
in a positive feedback loop by inflammatory cytokines, free fatty acids and 
oxidised cells and lipoproteins, which could be further contributed to from 
peripheral tissues such as adipose. This state recovers after the removal of tlie 
placenta but the underlying phenotypic or genetic abnormality persists until the 
development of clinical cardiac disease in later life.
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Therefore opportunities for future research include:
1. Prospective study of metabolic and inflammatory consequences of maternal 
obesity tlrioughout pregnancy: to establish if  pregnancy has any beneficial or 
detrimental effects on pre-existing vascular and metabolic abnormalities.
2. Relationship between maternal BMI and fetal indices of metabolic function 
(cord blood analyses of lipoprotein constituent, insulin, and inflammatory 
molecules); evidence for fetal progi amming effect of maternal obesity.
3. Follow up children and examine blood pressure and vascular function using 
laser Doppler imaging teclmique age 5.
4. Examine children of women 15-19 years postnatal (chapter seven) from pre­
eclamptic offspring versus controls (vascular function, insulin sensitivity): 
again implications for fetal programming and genetic inlreritance, i.e. cycling 
of risk factors tluough generations.
5. Case conhol study of inteiwention of moderate, regular exercise versus no 
exercise in pregnancy, firstly in relation to maternal vascular function and 
indices of insulin sensitivity and metabolic fimction and secondly, in relation 
to fetal indices (see point 2 above): role for exercise and weight loss to break 
the cycle of vascular risk.
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